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General introduction 
Coxiella burnetii emerged as a human pathogen in the Netherlands in May 2007 [1]. The 
small, Gram-negative intracellular bacterium has its natural reservoir in small ruminants 
(goats, sheep, cattle) and can cause acute Q fever in humans; a mostly self limiting febrile 
illness, presenting as a flulike syndrome, pneumonia or hepatitis [2,3]. Long-term sequelae 
of the acute disease are progression to chronic infection (mostly as endocarditis or infection 
of a vascular aneurysm), and the post Q fever fatigue syndrome (QFS); a state of prolonged 
symptomatology (especially fatigue) that can last for years, associated with a marked 
sustained decreased in health status [3].
The first Dutch human Q fever outbreak in 2007 (168 cases) heralded a recurring and 
expanding annual seasonal outbreak pattern (figure 1) for 2008 (1000 cases) and 2009 (2354 
cases), which were retrospectively linked to Q fever abortion waves on dairy goats and sheep 
farms farms starting in 2005 [4]. 
	 8 
General introduction  
Coxiella burnetii emerged as a human pathogen in the Netherlands in May 2007 [1]. The 
small, Gram-negative intracellular bacterium has its natural reservoir in small ruminants 
(goats, sheep, cattle) and can cause acute Q fever in humans; a mostly self limiting febrile 
illness, presenting as a flulike syndrome, pneumonia or hepatitis [2,3]. Long-term sequelae of 
the acute disease are progression to chronic infection (mostly as endocarditis or infection of 
a vascular aneurysm), and the post Q fever fatigue syndrome (QFS); a state of prolonged 
symptomatology (especially fatigue) that can last f r years, sociated with a marked 
sustained decreased in health status [3]. 
The first Dutch huma  Q fever o tbreak in 2007 (168 cases) heralded a recurring and 
expanding annual seasonal outbreak pattern (figure 1) for 2008 (1000 cases) and 2009 (2354 
cases), which were retrospectively linked to Q fever abortion waves on dairy goats and 
sheep farms farms starting in 2005 [4].  
 
Figure 1. Map of the Netherlands. Left: Number of human cases in 2007 and 2008. The red line shows the dairy 
goat and dairy sheep voluntary vaccination area in 2008. Right: Dairy goat farms (green) [24] and dairy sheep farms 
(blue) [2] with Q fever abortion history between 2005 and 2008 (adapted from [4]). 
At the outset of the epidemic, there were no validated protocols regarding diagnosis and 
follow-up of acute Q fever in the Netherlands [5]. Importantly, there was a lack of data on 
dynamics of the C. burnetii specific antibody response following acute Q fever and in case of 
chronic disease, as measured by comercially available kits. This posed a major challenge for 
Figure 1. Map of the Netherlands. Left: Number of human cases in 2007 and 2008. The red line shows the dairy 
goat and dairy sheep voluntary vaccination area in 2008. Right: Dairy goat farms (green) [24] and dairy sheep 
farms (blue) [2] with Q fever abortion history between 2005 and 2008 (adapted from [4]).
At the outset of the epidemic, there were no validated protocols regarding diagnosis and 
follow- p of acute Q fev r in the N therlands [5]. Importantly, there was a lack of data o  
dynamics of the C. burnetii specific antibody response following acute Q fever and in case 
of chronic disease, as measured by comercially available kits. This posed a major challenge 
for clinicians and other health care workers in managing acute disease and preventing long-
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term Q fever sequelae in the early stages of the epidemic [5,6]. 
After institution of drastic control measures including the culling of pregnant goats, the 
epidemic abated (figure 2) (504 cases in 2010, 81 cases in 2011) [5]. As of 2011, the Q fever 
disease burden amounted to more than 4000 notified human acute Q fever cases and an 
additional 44000 unnotified cases, as inferred from sero-epidemiological surveys [7,8]. 
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Figure 2. Acute Q fever notifications, The Netherlands, 1 January (week 1) 2007 – 30 november (week 48) 2011. 
(source: www.rivm.nl) 
 
By the time the acute Q fever epidemic declined, the long-term effects of the disease 
became increasingly apparent. Research focus shifted from detection and management of 
acute disease to diagnosis and management of chronic Q fever and QFS [9]. 
This introduction provides background information on C. burnetii as the causative agent of Q 
fever, Q fever disease manifestations including its long-term sequelae, the impact and scope 
of the Dutch Q fever outbreak 2007-2011 and a detailed description of the aims and outline 
of this thesis.   
 
History of Q fever 
Edward Holbrook Derrick described the febrile illness he encountered in abattoir workers in 
Queensland, Australia in 1937 as Q [for ‘query’] fever, “until fuller knowledge should allow a 
Figure 2. Acute Q fever notifications, The Netherlands, 1 January (we k 1) 2007 – 30 november (week 48) 2011. 
(source: www.rivm.nl)
By the time the acute Q fever epidemic declined, the long-term effects of the disease became 
increasingly apparent. Research focus shifted from detection and management of acute 
disease to diagnosis and management of chronic Q fever and QFS [9].
This introduction provides background information on C. burnetii as the causative agent of Q 
fever, Q fever disease manifestations including its long-term sequelae, the impact and scope 
of the Dutch Q fever outbreak 2007-2011 and a detailed description of the aims and outline 
of this thesis.  
History of Q fever
Edward Holbrook Derrick described the febrile illness he encountered in abattoir workers in 
Queensland, Australia in 1937 as Q [for ‘query’] fever, “until fuller knowledge should allow a 
better name” [10]. Despite elucidation of the causative agent, the animal reservoir and route 
of transmission shortly thereafter, the name Q fever has stuck. Suggestions of ‘abbatoir fever’ 
and ‘Queensland rickettsial fever’ were not favored, probably to avoid negative associations 
with either the meat cattle industry or the Australian state of Queensland [11]. In addition, 
researchers possibly just like to quote the catchy name of the disease in their article titles [3].
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Shortly after Derrick’s description of the disease, Frank Macfarlane Burnet (Australia) isolated 
the causative bacterium in humans [12]. Almost simultaneously, Herald Rea Cox (USA) 
isolated the same microorganism in ticks [13]. They showed that the etiological agent of Q 
fever had both viral and rickettsial properties. Therefore the initial name of the Q fever agent 
was Rickettsia burnetii. Later, a new genus named Coxiella was put forward, and the Q fever 
agent was renamed Coxiella burnetii, eponominously honouring both scientists who isolated 
the organism, but in the process leaving the disease’s discoverer’s name unmentioned [14]. 
The pathogen Coxiella burnetii
Coxiella burnetti is a small, pleomorphic, Gram-stain negative, intracellular coccobacillus 
ref raoult, parker. Sequencing of the C. burnetii 16S rRNA and genome has established a 
high degree of homology with Legionella pneumophila; both bacteria belong to the gamma 
division of proteobacteria [3]. 
Morphologically, C. burnetii has a unique lifecycle in which 2 distinct forms can be identified, 
both with different densities and antigenic properties (figure 3). The ‘large cell variant’ (LCV) 
is metabolically active and is the intracellularly living form of C. burnetii.  The extracellular 
‘small cell variant’ (SCV) is metabolically inactive and can withstand intense environmental 
physical conditions and exposure to chemical agents, allowing prolonged survival in the 
environment of C. burnetii in this particular form [2,3]. 
In addition to these distinct morphological forms, C. burnetii can undergo phase variation 
into two distinct antigenic forms known as phase I and phase II. Antigenic phase II is less 
virulent and has marked differences in lipopolysaccharide (LPS) compared to the highly 
infectious wild-type form; antigenic phase I [2,3]. Phase I C. burnetii are isolated from 
specimens from infected humans. Phase II organisms can only be isolated in the laboratory 
following serial passage in fertilised eggs or tissue cultures. Morphologically, these two 
forms are indistinguishable when observed under a microscope. The antigenic phase shift 
is reflected in the host’s antibody response to infection with C. burnetii and as such is used 
as a diagnostic tool [2,3]. Contrary to expectation, however, the antibody response in acute 
disease is mainly directed against phase II organisms whereas in chronic disease antibody 
titres against phase I organisms predominate [3] . 
Chapter 1
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Figure 3. electron microscope image of C. burnetii showing the LCV and SCV forms (presented at the Seminar 
on Q fever in Cambridge, 26th of July 2008, courtesy of prof. BP Marmion).
Human infection
Q fever is a zoonosis with a widespread global distribution, notable exceptions being New 
Zealand and the continent of Antarctica [3]. The main animal reservoir of C. burnetii is small 
ruminants; goats, sheep and cattle, but also outbreaks related to pets and even wildlife have 
been described [2, 15]. Infected mammals shed large quantities of C. burnetii organisms in 
milk, urine, faeces and the products of parturition [2,3]. In the environment, the SCV form 
of C. burnetii can survive outside of the host for prolonged periods of time. C. burnetii 
contaminated dust particles  particles can be taken up in aerosols, become airborn and 
carried by the wind, spread out over extensive geographical areas spanning kilometers [16]. 
Human infection mainly occurs by way of inhalation of contaminated dust or aerosols, rarely 
by direct contact with animal birth products or ingestion of infected animal dairy products 
such as milk or cheese [2,3]. Human-to-human transmission is extremely rare, but Q fever has 
been reported to follow breast milk feeding, sexual intercourse, bone marrow transplant and 
blood transfusion [2,17,18]. There are 2 earlier reports on respiratory spread after autopsies, 
and 1 case of infection of an obstetrician attending an infected pregnant woman, whose 
prematurely aborted fetus was also infected by vertical transmission of C. burnetii [19].
The host’s immune response to C. burnetii
As is the case for other intracellular pathogens, both cell-mediated immunity and humoral 
immune mechanisms play an important role in the host’s defence against C. burnetii infection. 
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T-cells and their associated cytokines, interferon-gamma being the most potent, have a 
pivotal role in countering primary C. burnetii infection and subsequent clearance or control 
of the intracellular pathogen [20]. The host’s humoral immune response is characterised by 
antibody formation against both phase II and phase I antigens due to the antigenic phase 
variation of C. burnetii earlier described in this chapter.
Once the host has inhaled the contaminated aerosols, C. burnetii targets resting alveolar 
macrophages and other mononuclear phagocytes. After being engulfed and phagocytised 
by these cells, C. burnetii survives in a slightly acidic phagosome (pH 4,5) [21,22].
In primary infection, these C. burnetii laden phagosomes fuse with lysosomes to form 
phagolysosomes. Subsequently infected host cells undergo apoptosis, thereby controlling the 
infection. This process of phagolysosome fusion and apoptosis is very likely to be controlled by 
a T cell-mediated immune response, requiring interferon-gamma (IFN-gamma) [22,23]. 
In chronic Q fever patients, this IFN-gamma-mediated microbicidal capacity of mono- and 
macrophages is inhibited by over-production of inhibitory cytokines such as IL-10 [23]. 
In patients with post Q fever fatigue syndrome, there is some evidence to suggest an enhanced 
cell mediated immune response contributing to or causing the protracted symptoms. It has 
been put forward that this dysfunctional immune reponse is triggered by a persistence of C. 
burnetii specific antigens in the host after primary infection [24,25]. However, the putative 
role of the host’s immune response in the pathophysiology of QFS remains to be elucidated 
and confirmed by other research groups. 
Clinical manifestations of Q fever
Q fever is an infectious disease with a wide array of clinical manifestations, either acute or 
chronic. The clinical course (figure 4) can range from asymptomatic serocoversion to acute 
disease to  to development of long-term complications such as the post Q fever fatigue 
syndrome and chronic Q fever in patients at risk.
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A reported 50-60% of primary C. burnetii infections remain subclinical [2,3]. These patients 
exhibit no symptoms but can be at risk for later development of chronic Q fever. In the 
Netherlands the reported proportion of asymptomatic cases is much higher, with an 
estimated 12,6 unnotified incident cases for every notified Q fever case [8]. 
When symptomatic, primary infection with C. burnetii is called acute Q fever. After an 
incubation period of two to three weeks, most patients experience a rather sudden onset of 
a flu-like illness consisting of fever, headache, myalgia, fatigue and respiratory symptoms. 
Atypical pneumonia as defined by respiratory symptoms including chest x-ray abnormalities 
can be a more clinically severe presentation of acute Q fever. Severe acute hepatitis has 
been described by some authors, but has not been encountered in the Netherlands. Of note, 
however, slightly elevated liver function (transaminase) are often found in acute Q fever, but 
without clinical signs of hepatitis such as jaundice or abdominal pain [2,3]. Symptoms can 
last up to 3 months and generally resolve spontaneously. Antibiotic therapy shortens the 
symptomatic period and can speed up recovery of pneumonia. Doxycycline is the first line 
treatment for acute Q fever (200mg/day for 14 days), alternative antibiotics being co-
trimoxazol or a quinolone. Hospitalisation rates for acute Q fever are reportedly low at 2%, 
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Primary C. burnetii infection; asymptomatic seroconversion or acute Q fever
A reported 50-60% of primary C. burnetii infections remain subclinical [2,3]. These patients 
exhibit no symptoms but can be at risk for later development of chronic Q fever. In the 
Netherlands the reported proportion of asymptomatic cases is much higher, with an 
estimated 12,6 unnotified incident cases for every notified Q fever case [8].
When symptomatic, primary infection with C. burnetii is called acute Q fever. After an 
incubation period of two to three weeks, most patients experience a rather sudden onset of 
a flu-like illness consisting of fever, headache, myalgia, fatigue and respiratory symptoms. 
Atypical pneumonia as defined by respiratory symptoms including chest x-ray abnormalities 
can be a more clinically severe presentation of acute Q fever. Severe acute hepatitis has 
been described by some authors, but has not been encountered in the Netherlands. Of note, 
however, slightly elevated liver function (transaminase) are often found in acute Q fever, 
but without clinical signs of hepatitis such as jaundice or abdominal pain [2,3]. Symptoms 
can last up to 3 months and generally resolve spontaneously. Antibiotic therapy shortens 
the symptomatic period and can speed up recovery of pneumonia. Doxycycline is the first 
line treatment for acute Q fever (200mg/day for 14 days), alternative antibiotics being co-
trimoxazol or a quinolone. Hospitalisation rates for acute Q fever are reportedly low at 2%, 
depending on outbreak characteristics [2]. In the Netherlands hospitalisation rates in 2007 
were much higher at 46%, dropping to 21% in 2009 [26]. The mortality rate of hospitalisation 
with acute Q fever in the Netherlands is an estimated 1%, tallying with earlier reports from 
France and the United Kingdom [27].
Q fever: long-term clinical outcome
Post-Q fever fatigue syndrome
Following the acute Q fever episode a large proportion of patients experience protracted 
symptomatology and a sustained decrease in health status generally referred to as the post-Q 
fever fatigue syndrome (QFS [28,29]. In contrast with chronic Q fever, which is a persistent 
infection with C. burnetii, in QFS no viable C. burnetii bacteria have ever been isolated. In 
addition the antibody titres in QFS patients are similar to those who fully recovered from 
primary C. burnetii infection.  
Research groups in England, Australia and Canada have reported on a decreased health 
status in Q fever patients, using various questionnaires and study methods [28-30]. QFS’s 
hallmark feature is persistent, excessive and undue fatigue, other symptoms being fatigue 
night sweats, headache, myalgia, arthralgia, dyspnea and blurred vision [28]. The incidence 
of QFS ranges from 20 to 42% and can last up to ten years after primary infection [28-30]. 
Despite these reports, the acceptance of QFS as a distinct disease entity, however, is not 
universal [31]. Indeed, post-infectious protracted fatigue syndromes have been reported 
for several other bacterial and viral pathogens such as Borrelia burgdorferi, Legionella 
pneumophila, Epstein Barr virus and West Nile Virus [32,33]. 
In addition, a lack of clear definition of QFS, small patient numbers in studies and different 
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study protocols do not allow for readily comparison of data and validation of obtained 
results.
Furthermore, the pathophysiology of QFS remains to be elucidated, but severity of the 
acute Q fever illness, genetic polymorphisms and abnormal and dysfunctional host immune 
response to C. burnetii infection have all been implicated [34-38]. Recently a new QFS 
paradigm has been put forward postulating a heightened dysfunctional immune respons 
[24]. 
In clinical practice, QFS patients remain indistinguishable from patients with a complete 
recovery after primary infection with C. burnetii. QFS patients do not meet the criteria for 
chronic Q fever and C. burnetii specific antibody titres are comparable [28-30]. QFS remains 
a purely clinical diagnosis.
In the Netherlands, QFS causes prolonged morbidity in a large section of Q fever patients and 
accounts for the largest portion of the total disease burden in socioeconomic terms due to 
increased  healthcare consumption and absence from work [39].
Chronic Q fever
Primary C. burnetii infection, both symptomatic and asymptomatic, will develop into chronic 
Q fever in 1-5% of patients with an incubation period varying from months to years [2,3]. 
Until recently, endocarditis was reported to account for 75% of all chronic Q fever cases. In 
the Netherlands, however, infection of aortic aneurysms and vascular prosthesis is more 
prevalent, closely followed by endocarditis [40,41]. Less frequent clinical presentations of 
chronic infection with C. burnetii are pericarditis, hepatitis, osteomyelitis and placentitis in 
case of chronic Q fever in pregnancy [2,3].
Risk factors for development of chronic Q fever are increasing age, cardiac valve defects, 
vascular grafts and aneurysms, immunosuppression, and pregnancy [2,3]. Recently, 
Kampschreur et al. identified  renal insufficiency as an independent risk factor [42]. The risk 
of developing chronic Q fever in case of known or previously unknown pre-existing cardiac 
valvulopathy has been estimated by one research group to be as high as 39%. This has led to 
the recommendation to perform an echocardiogram in every Q fever patient and start long-
term antibiotic prophylaxis in case of any, be it trivial or clinically significant, cardiac valve 
defect [43-45]. 
Chronic Q fever has a very high mortality when left untreated. Timely diagnosis and start 
of antibiotic treatment has dramatically decreased mortality rates over the last years. 
Treatment of chronic Q fever consists of long-term administration of antibiotics for at least 
18 to 24 months, preferably a combination of doxycycline and hydroxychloroquine [2,3]. 
Chloroquine heightens the pH in the phagoloysosome, thereby enhancing the efficacy of 
doxycycline when used in combination. The toxicity of this regimen is considerable and is 
rarely mentioned in articles on chronic Q fever and the prevention of disease in patients at 
risk. Doxycycline associated photosensitivity is reported in up to 100% of patients on long-
term treatment [46,47]. Other frequently reported adverse effects are nausea, dizziness 
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and headache. In addition patients need to undergo regular ophtalmologic examinations 
as hydroxychloroquine can cause irreversible maculopathy. Intensive counselling and 
monitoring of therapeutic drug levels is required to secure optimal treatment regimen 
adherence [47].
Diagnosis of Q fever
A diagnosis of C. burnetii infection can be made by demonstrating in the host: 1) C. burnetii 
specific phase I and/or phase II antibodies, 2) the bacterium or (components of) its DNA in 
blood or tissue, 3) a C. burnetii specific cellular immune respons. Establishing a diagnosis 
of acute Q fever differs from that of chronic Q fever, the latter being a complex diagnosis 
based on a combination of symptomatology, detection of C. burnetii DNA, serology, host 
characteristics and diagnostic imaging techniques [40].  
Cultivation of C. burnetii is not routinely undertaken because it is laboursome, time-
consuming, has a low sensitivity for detecting the organism and requires a biosafety level 3 
laboratory. Measuring the host’s cellular immune reponse to C. burnetii in humans has been 
performed in experimental settings, including Q fever vaccination studies [48]. However, to 
date, there is no validated test measuring C. burnetii specific cellular immunity in humans, in 
order to diagnose acute Q fever or its long-term sequelae; chronic disease and QFS.
In routine daily clinical practice, diagnosis of acute Q fever relies almost exclusively on 
serology [2,3]. The most frequently used serological test is the immunofluorescence assay 
(IFA), but enzyme-linked immunosorbent assay (ELISA) or complement binding reaction 
(CBR) are widely used as well. The antibody response, however, can take up to 15 days after 
onset of symptoms. As a consequence of the antigenic phase variation of C. burnetii, the 
host’s humoral immune response is characterised by antibody formation against both phase 
II antigens, which paradoxically appear first (as the virulent form of C. burnetii is phase I), and 
subsequently against phase I antigens (figure 5). 
In recent years, PCR on serum has proven to be a valuable additional diagnostic tool in the 
early stages of primary infection. In the Netherlands, Schneeberger et al. showed a sensitivity 
of C. burnetii PCR on serum of >90% in the early stages of acute Q fever. The latest time point 
at which PCR was positive being 17 days after onset of symptoms. PCR invariably became 
negative as the serological response fully developed [49]. 
In chronic Q fever, viable C. burnetii bacteria persist in the host after primary infection. The 
onset of chronic Q fever can be insidious and it can take several months up to many years 
before the disease becomes clinically apparent. When symptoms do occur, they are often 
non-specific [2,3]. 
Establishing a chronic Q fever diagnosis can be difficult, as it based on a combination of 
symptomatology, detection of C. burnetii DNA, serology, host risk factors and diagnostic 
imaging techniques [40]. A positive PCR in blood or tissue in the absence of acute Q fever 
is proof of chronic Q fever, but sensitivity is low [51]. A high titre of phase I IgG might be 
indicative of chronic disease but has low positive predictive value on its own and should 
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therefore always be interpreted in combination with clinical findings and results of imaging 
studies. In medical literature, the widely cited cut-off value for phase I IgG of >1:800 was 
established using an in-house IFA developed in France [2,52]. As this test is not routinely 
available, a commercially available IFA (Focus diagnostics) is used in the Netherlands, and a 
cut-off value of =/>1:1024 is considered to be indicative of chronic disease [40]. 
	 17 
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Figure 5. Idealised antibody response in acute Q fever as measured by IFA (from Munster et al. [50]; original from 
B.P. Marmion: Q fever; your questions answered. St Leonards, N.S.W. Medimedia Communications, 1999) 
 
Q fever in the Netherlands: Coxiella burnetii as emerging pathogen 
In the Netherlands, Q fever has been a mandatory notifiable diseasee since 1975. Before 
2007, between 1 and 37 cases were reported annually, with an average of 17 cases per year 
[4].  
In May 2007, an oubreak of atypical pneumonia cases was reported by a general practitioner 
in Herpen, a small rural village in the province of Noord Brabant, in the southern part of the 
Netherlands. In a 10 day period, 9 patients presented with flu-like symptoms and dyspnea 
and 6 of them were admited to hospital with a clinical suspicion of pneumonia. A few days 
prior, a medical microbiologist in the same region had reported to the public health service 
two cases of severe pneumonia unresponsive to antibiotics. Retrospective serological 
investigation on serum samples of 48 patients showed presence of Mycoplasma pneumonia 
IgM antibodies in 7 of the first 19 sera tested, so initially a local M. pneumonia outbreak was 
suspected. Meanwhile, sera from 3 hospitalised patients from Herpen tested positive in the 
IFA test for C. Burnetii. Targeted testing for C. burnetii antibodies of the earlier collected sera 
Figure 5. Idealised antibody response in acute Q fever as measured by IFA (from Munster et al. [50]; original 
from B.P. Marmion: Q fever; your questions answered. St Leonards, N.S.W. Medimedia Communications, 1999)
Q fever in the Netherlands: Coxiella burnetii as emerging pathogen
In the Netherlands, Q fever has been a mandatory notifiable diseasee since 1975. Before 2007, 
between 1 and 37 cases were r ported annu lly, with an average of 17 cases per y ar [4]. 
In May 2007, an oubreak of atypical pneumonia cases was reported by a general practitioner 
in Herpen, a small rural village in the province of Noord Brabant, in the southern part of the 
Netherlands. In a 10 day p ri d, 9 p tients presented with flu-like symptoms a d dyspnea 
and 6 of them were admited to hospital with a clinical suspicion of pn umonia. A few days 
prior, a medical microbiologist in the same region had reported to the public health service 
two cases of severe pneumonia unresponsive to antibiotics. Retrospective serological 
investigation on serum samples of 48 patients showed presence of Mycoplasma pneumonia 
IgM antibodies in 7 of the first 19 sera tested, so initially a local M. Pneumonia outbreak was 
suspected. Meanwhile, sera from 3 hospitalised patients from Herpen tested positive in the 
IFA test for C. Burnetii. Targeted testing for C. burnetii antibodies of the earlier collected sera 
using the complement binding reactio  (CBR) was positive in 13 of th  48 sera. The putative 
causative agent of the outbreak was changed from  M. Pneumoniae to C. burnetii [1,4]. 
This was the beginning of the first Dutch human Q fever outbreak that would entail 168 
notified cases in 2007. Successive annual seasonal outbreaks in 2008 (1000 cases) and 2009 
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(2354 cases) spread out over a larger geographical area. In 2008 a definitive link to dairy goat 
farming was established and several measures controlling the dairy goat farming industry 
followed, eventually culminating in the culling of pregnant goats on infected farms starting 
in december 2009. In 2010 the Q fever epidemic abated and by 2011 the number of Q fever 
cases fell below the number of patients in 2007. By 2011 more than 4000 Q fever patients had 
been diagnosed with Q fever [4]. 
The majority of patients described in the studies of this thesis (Chapter 2 to 6) were diagnosed 
with Q fever in the initial stages of the outbreak and were followed up at the GP practice in Herpen.
Outline and aims of the thesis
The aim of this thesis is to describe observations on epidemiology, clinical aspects and long 
term health outcomes of Q fever patients diagnosed in the initial stages of the first Dutch 
human Q fever outbreak. In addition, this thesis aims to describe the potential clinical use of 
a newly developed diagnostic Q fever interferon gamma release assay, the Coxiella ELISPOT, 
which measures the host’s cellular immune reponse to Coxiella burnetii. 
Q fever is considered a new and emerging zoonosis in the Netherlands. Retrospective 
serological studies perfomed on available samples from the period leading up to the first Q 
fever outbreak in the Netherlands show a low seroprevalence of antibodies againt C. burnetii 
[53]. However, the highly epidemic municipalities in the epidemic’s epicentre in the province 
of Noord-Brabant were excluded from analysis [54]. A description of the aetiology of clinically 
treated pneumonia cases in the epicentre of the first Q fever outbreak in 2007 is given in 
Chapter 2. The clinical presentation, diagnosis including antibody response and clinical 
outcome of Q fever in the Netherlands were unknown at the onset of the first epidemic wave 
in 2007. Available literature on the disease in its acute and chronic form, its diagnosis and 
management, was mostly retrospective and mainly derived from a single reference centre 
of expertise in France. Chapter 3. describes the follow-up in terms of clinical presentation, 
serology and echocardiographic findings of Dutch Q fever patients from the epicentre of the 
first outbreak. Chapter 4. describes the echocardiographic findings and outcomes of a larger 
group of Q fever patients from both the 2007 and 2008 cohort. In Chapter 5. the health status 
of Q fever patients from the first outbreak cohort is studied in detail, using a case-control 
design. In Chapter 6. the health status of the same cohort of patients is studied 4 years 
after acute Q fever, allowing for a direct comparison of detailed health status assessment 
on a group- and individual patient’s level . Chapter 7. deals with the development and 
validation of the Coxiella ELISPOT; a Coxiella burnetti specific interferon gamma release assay 
(IGRA) measuring C. burnetii specific T-cell responses to both C. burnetii phase I and phase 
II antigens. In Chapter 8. the Coxiella ELISPOT is compared to a different whole blood C. 
burnetii specific IGRA in terms of diagnostic potential. Chapter 9. summarises the findings of 
the present thesis and formulates implications and opportunities for further research.
General introduction and outline of the thesis
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Abstract
Despite a reported low seroprevalence in the Netherlands in the period leading up to the outbreak, the 
question whether C. burnetii emerged as a cause of pneumonia in the geographical epicentre of the first 
Q fever outbreak in 2007 remained unanswered. 
The contribution of C. burnetii as a causative agent of pneumonia in patients admitted to Bernhoven 
Hospital in the period January-July 2007 was assessed by retrospectively testing available patients’ sera 
for the presence of C. burnetii antibodies. Of the total of 95 clinical pneumonia cases, C. burnetii was the 
causative agent in 21 (22%). The number of Q fever pneumonia cases in May (n=13) was significantly 
higher than in any other month of the study period (range 0-5). To examine these findings in a historical 
perspective, data on number of pneumonia cases treated at Bernhoven Hospital were retrieved from 
the local diagnosis registration system. In the 2 years preceding the outbreak, the number of pneumonia 
cases was stable with expected seasonal variation in 2005 (206 cases) and 2006 (170 cases), but with no 
sharp increase as was observed in 2007 (n=272). 
The findings in this study support the hypothesis that C. burnetii emerged as a novel etiological agent 
of pneumonia in the epidemic area in the Netherlands in May 2007.
Coxiella burnetii: a genuinely novel causative agent of pneumonia in the Netherlands 
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Coxiella burnetii: a genuinely novel causative agent of pneumonia in 
the Netherlands since May 2007
Q fever is considered a new and emerging zoonosis in the Netherlands since the first reported 
outbreak in late spring 2007 [1]. In support of this hypothesis, Schimmer et al. recently 
reported a low seroprevalence of 2,4% in the Netherlands in the period leading up to the 
outbreak (February 2006 – June 2007) retrospectively testing sera from the Dutch National 
Immunization Programme available from randomly selected municipalities all over the 
country [2]. However, the highly epidemic municipalities of 2007-2010 were excluded from 
the study sample, leaving unanswered the question whether Coxiella burnetii emerged as a 
genuinely novel infectious agent in those areas in May 2007. 
We present here data from a retrospective study performed in the geographical epicentre 
of the first Q fever outbreak, investigating the etiology of clinically treated pneumonia 
cases, in the period leading up to the first reported outbreak. The outbreak’s epicentre was 
located in the rural village of Herpen, in the province of Noord-Brabant. Herpen lies within 
the catchment area (catchment population 190000) of the nearby located community based 
Bernhoven hospital in Oss. 
Aim of this study was to determine the contribution of Coxiella burnetii as a causative 
agent of pneumonia in patients admitted for pneumonia to the Bernhoven hospital, in the 
period January to July 2007. Pneumonia cases were identified retrospectively by retrieving 
all entries for ‘pneumonia’ from the hospital’s electronic diagnosis registration system. A 
pneumonia case was defined by the presence of one or more clinical compatible symptoms 
(fever, cough, dyspnea, headache) and a (new) infiltrate or consolidation on chest imaging 
(chest x-ray or CT scan). If no causative agent had already been identified using standard 
cultures and serology, available sera were tested retrospectively for Coxiella burnetii, using 
both complement fixation test (CFT) and PCR. 
Of the total of 95 clinical pneumonia cases identified, C. burnetii was the causative agent in 
21 patients (22%). These patients showed a fourfold increase in CFT in paired samples. One Q 
fever patient had a positive serum PCR with negative CFT at presentation, but seroconverted 
in the follow-up CFT sample taken 3 months later.
In 7 cases (7%), a pathogen other than C. burnetii was found, in 23 cases (24%) no cause was 
found after serological testing. In the remaining 44 cases (47%) serology could not be obtained 
(Figure 1.). Mean number of pneumonia cases was 13 per month (range 5-29). The number 
of Q fever pneumonia cases in May (13) was significantly higher than any other month in the 
study period (range 0-5) (p<0,05). For all other groups (other pathogen, unknown etiology, no 
serology available), the number of cases did not differ significantly between months in the 
study period (p>0,05 for all groups). The contribution of Coxiella burnetii as a causative agent 
of clinically treated pneumonia sharply increased in May 2007 compared to January to April 
2007. There was no evidence of underreporting of Q fever pneumonia in the period leading 
up to the outbreak. 
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In order to examine these data further in a historical perspective, we retrieved data on number 
of pneumonia cases from the local diagnosis registration system from the Bernhoven hospital 
for 2005 and 2006. In the 2 years preceding the 2007 outbreak, the number of pneumonia cases 
was stable with expected seasonal variations in 2005 (206 cases) and 2006 (170 cases), but 
with no sudden sharp increase as was observed in 2007 (272 cases). This significant increase in 
number of pneumonia cases, especially in late spring and summer, further supports the notion 
of the introduction of Coxiella burnetii as a new etiological agent of pneumonia in this region. 
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Figure 1. Etiology of pneumonia cases in the Bernhoven Hospital in the period leading up to the first reported Dutch 
Q fever outbreak. 
 
A Q fever diagnosis can easily be overlooked as symptoms are non specific and the clinical 
course is generally mild. In addition, sheer unfamiliarity with Coxiella burnetii as an infectious 
agent could have led to an underreporting of Q fever cases by attending physicians. 
Interestingly in this regard, Van den Wijngaard et al. found retrospective statistical evidence 
Figure 1. Etiology of pneumonia cases in the Bernhoven Hospital in the period leading up to the first reported 
Dutch Q fever outbreak.
A Q fever diagnosis can easily be overlooked as symptoms are non specific and the clinical 
course is generally mild. In addition, sheer unfamiliarity with Coxiella burnetii as an infectious 
agent could have led to an underreporting of Q fever cases by attending physicians. 
Interestingly in this regard, Van den Wijngaard et al. found retrospective statistical evidence 
of clustering of hospitalisations of possible and plausible Q fever pneumonia cases starting 
as early as 2005 [3]. However, lack of serological testing precluded definite confirmation of 
these outbreak clusters as being caused by Q fever. 
Our data support the hypothesis that Coxiella burnetii emerged as a novel etiological agent 
of pneumonia in the epidemic area in the Netherlands in May 2007.
Coxiella burnetii: a genuinely novel causative agent of pneumonia in the Netherlands 
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Abstract
Purpose 
In 2007, a large goatfarming associated Q fever outbreak occurred in the Netherlands. Data on clinical 
outcome of Dutch Q fever patients are lacking. The current advocated follow-up strategy includes 
serological follow-up to detect evolution to chronic disease and cardiac screening at baseline to identify 
and prophylactically treat Q fever patients in case of valvulopathy. However, serological follow-up using 
commercially available tests is complicated by lack of validated cut-off values. Furthermore, cardiac 
screening in the setting of a large oubreak has not been implemented before. Therefore, we report here 
the clinical outcome, serological follow-up and cardiac screening data of the Q fever patients of the 
current ongoing outbreak.
Methods 
Implementation of a protocol including clinical and serological follow-up at baseline 3, 6 and 12 
months after acute Q fever and screening echocardiography at baseline.
Results 
Eighty-five patients with acute Q fever were identified (male 62%, female 38%). An aspecific, flu-like 
illness was the most common clinical presentation. Persistent symptoms after acute Q fever were 
reported by 59% of patients at 6 months and 30% at 12 months follow-up. We observed a typical 
serological response to Coxiella burnetii infection in both anti-phase I and anti-phase II IgG antibodies, 
with an increase in antibody titers up to 3 months and a subsequent decrease in the following 9 months. 
Screening echocardiography was available for 66 (78%) out of 85 Q-fever patients. Cardiac valvulopathy 
was present in 39 (59%) patients. None of the 85 patients developed chronic Q fever.
Conclusions
Clinical, serological and echocardiographic data of the current ongoing Dutch Q fever outbreak cohort 
are presented. Screening echocardiography is no longer part of the standard work-up of Q fever patients 
in the Netherlands. 
One-year follow-up of the ongoing Dutch Q fever outbreak: 
clinical, serological and echocardiographic findings 
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Introduction
In late spring 2007, a large Q fever outbreak in The Netherlands occurred in the province of Noord 
Brabant with a distinct epidemic centre around the town of Herpen [1]. Although no definitive 
source for the outbreak was identified, the preceding increased abortion rate amongst goats in 
the region suggested these ruminants as being the most likely reservoir [2,3]. 
Q fever is an ubiquitous zoonosis caused by the obligate intracellular bacterium Coxiella 
burnetii. The clinical manifestations of this acute infection are usually self-limiting and range 
from a mild flu-like febrile illness to atypical pneumonia and hepatitis [4]. Serological and 
clinical follow-up after primary infection is recommended because approximately 1-5% of 
patients will develop chronic Q fever, endocarditis being the clinical manifestation in 60-70% 
of cases [5]. Cardiac valve abnormalities, vascular prosthesis, compromised immunity and 
pregnancy constitute predisposing host factors for chronic Q fever [6]. Recently screening 
echocardiography has been added to the standard of care for Q fever patients [7,8]. In daily 
clinical practice however, adequate follow-up of patients after acute Q  fever has practical 
difficulties. First, interpretation of serology obtained by commercially available tests is 
hampered by incomplete knowledge of the natural course of the antibody reponse to Coxiella 
burnetii and lack of validated cut-off values for chronic disease. Second, minor cardiac 
valvulopathies are frequently encountered in the general population, raising the question 
whether indeed all patients with cardiac valve abnormalities should receive prolonged 
prophylactic antibiotic treatment.
Faced with the forementioned Q fever outbreak in the Netherlands, a follow-up protocol was 
implemented, including clinical and serological follow-up for a 1-year period and Q fever 
patients were offered a screening echocardiography at baseline. The aim of this paper was 
to report the clinical characteristics and outcome, serological data and echocardiographic 
findings of the current ongoing Q fever outbreak in the Netherlands.
Methods
Q fever case definition 
A case of acute Q fever was defined as any inhabitant of the outbreak cluster area who 
presented with one or more compatible clinical symptoms (fever, fatigue, chills, headache, 
myalgia, sweats, cough [4]) and demonstration of infection with Coxiella burnetii as evidenced 
by 1) a seroconversion or fourfold increase of antibody titer using a C. burnetii complement 
fixation test (CFT) in samples taken at least 14 days apart, 2) presence of both anti-phase 
II IgM and anti-phase II IgG antibodies in the C. burnetii Immunofluorescence Assay (IFA) 
with a 1:64 or greater dilution [1], or a positive serum PCR. For patients admitted to hospital 
and presenting with pneumonia, the severity of disease was assessed using the Pneumonia 
Severity Index (PSI) [9]. 
A case of chronic Q fever is defined as any inhabitant of the outbreak cluster area with a 
clinical entity compatible with chronic Coxiella burnetii infection as described in the literature 
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by Raoult (endocarditis, vascular infection, osteoarticular infection, chronic hepatitis, 
pregnancy), in the presence of an anti-Phase-I IgG titer ≥ 800, for ≥ 6 months after the initial 
day of illness [4,10]. 
Follow-up protocol
The follow-up protocol consisted of a complete history and physical examination at 6 and 
12 months after the initial day of illness, serological testing at baseline followed by testing 
after 3, 6 and 12 months after a referral to a cardiologist for a single screening transthoracic 
echocardiogram. Data on symptoms were obtained by asking the patient an open question 
on the presence of any complaints. No structured questionnaire was used. As the Q fever 
outbreak was identified retrospectively, data on presenting symptoms at baseline were 
collected through review of all available medical records at the GP practice. Since this 
concerned an observational study, all interventions had been part of standard care. Therefore, 
patients were asked to cooperate and no specific ethical approval for this study was sought.
Serology and PCR
Sera were tested for Coxiella burnetii antibodies using a Complement Fixation Test (CFT, 
Institute Virion/Serion, GmbH, Würzburg, Germany), testing only anti-phase II antibodies, 
and an Immunofluorescence Assay (IFA, Focus Diagnostics, Cypress, California 90630, U.S.A.), 
assessing IgM and IgG antibodies to both phase I and II antibodies. Sera taken at baseline 
(T=0) were also tested by Polymerase Chain Reaction (PCR) as described in the literature [11]. 
The respective time-points for final analysis were defined as follows: baseline (T=0) is the date 
of the first available serological results within 6 weeks after the first day of illness. Serological 
results at 3 (T=3), 6 (T=6) and 12 months (T=12) after first day of illness were included if blood 
samples were drawn at these time points, with a margin of plus or minus 1 month. 
Screening echocardiography
Structural cardiac abnormalities and valvular defects were classified according to the ASE 
guidelines [12-15]. The ASE guidelines are a consensus statement of the American College 
of Cardiology, the American Heart Association and the European Society of Cardiology. 
These guidelines provide a framework for standardized assessment of severity of valvular 
regurgitation and –stenosis, using well defined structural-, Doppler- and quantitative 
echocardiographic parameters. Major (or clinically significant) valvulopathies are defined 
as moderate and severe regurgitation or stenosis of the mitral and/or aortic valve. Minor 
valvulopathies are defined as trace or mild regurgitation or stenosis of the mitral and/or aortic 
valve, a bicuspid aortic valve and mitral valve prolaps without significant accompanying 
stenosis or regurgitation. 
Data to calculate percentages were analysed using Microsoft Excell 7.0 and SPSS 17.0. 
GraphPad Prism 4.0 was used to make Figure 1.
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Results 
The Herpen Q fever outbreak cohort 
A total of 85 patients with acute Q fever were identified in the outbreak cluster. Patient 
characteristics are given in Table 1.
The male-to-female ratio was 1,7. None of the female patients was pregnant. Co-morbidity 
was present in 26 patients (31%). Six patients had a known risk factor for developing 
chronic Q fever: 4 patients with previously documented significant cardiac valvulopathies, 
1 patient using long-term high dose corticosteroids for idiopathic trombocytopenic purpura 
and 1 patient with an aortic vascular prosthesis. Complete baseline and follow-up data on 
symptoms and physical examination were available for all patients and are given in Table 2. 
An aspecific, flu-like illness was the most common clinical presentation. All patients who 
were admitted to hospital (8 female, 16 male) presented with (atypical) pneumonia and 83% 
of these patients had a Pneumonia Severity Index (PSI) of class I or class II, representing a low 
disease severity [9]. At 6 months follow-up, more than half of all Q fever patients had persistent 
symptoms, fatigue being the most prevalent complaint. At one year, reports of persistent 
symptoms had roughly halved. Twenty-six percent of patients still reporting fatigue which 
they attributed to their acute Q fever episode. None of the 85 patients had developed chronic 
Q fever at the one-year follow-up point. One male patient died of a myocardial infarction at 8 
months follow-up, unrelated to Q fever. 
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Serology
Serological data were available at baseline (68%), at 3 month follow-up (49%), at 6 month follow-
up (81%) and at 12 month follow-up (75%). Results are shown in figure 1. CFT and IFA showed 
similar profiles, but at a different titer level. 
The numbers of patients with an anti-pase I IgG titer of equal or more than 800 (suggesting 
chronic disease) at the respective timepoints were 7 (T=0), 21 (T=3), 13 (T=6) and 2 (T=12). PCR was 
performed on 60 out of 85 first available sera. Seven of these 60 patients (11,6%) had a positive 
PCR and negative serology. All PCR positive patients subsequently seroconverted after 3 months. 
	 32 
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Echocardiography
Screening transthoracic echocardiography was available for 66 (78%) out of 85 Q-fever 
patients. The remaining nineteen patients repeatedly failed to show up at their appointment 
for a transthoracic echocardiogram.  Results are shown in Table 3. Cardiac valvulopathy was 
present in 39 (59%) patients, five of whom had a major or clinically significant (moderate or 
severe) valvulopathy. Four of these five patients were previously known to have a cardiac 
valvulopathy. One patient had a bicuspid aortic valve associated with a moderate aortic 
insufficiency, This anomaly was classified as a clinically significant valvulopathy. The 
remaining 34 patients had one or more minor cardiac valvular abnomalities. 
	 33 
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Figure 1. One-year follow-up of patients with acute Q fever by complement fixation test (CFT; antibodies to phase 
II) and immunofluorescence assay (IFA; IgG- and IgM-antibodies to phase I and phase II). The horizontal bars 
represent the mean. 
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phase II) and immunofluorescence assay (IFA; IgG- and IgM-antibodies to phase I and phase II). The horizontal 
bars represent the mean.
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Discussion
As expected, an aspecific, flu-like syndrome with or without signs of respiratory tract infection 
was the main clinical Q fever manifestation in this remarkably compliant cohort of patients. 
However, chest radiography was only performed in patients admitted to hospital, which could 
underestimate the prevalence of pneumonia in patients treated by their GP. Males were more 
likely to suffer from symptomatic Q fever than females, which is a well known phenomenon 
and appears to be the result of the gender related expression of sex hormones [16]. 
Fatigue was noted by Q fever patients in 52% at 6 months and 26% at 1 year following primary 
infection. Other research groups, using various questionnaires, have reported a comparably 
high proportion of fatigued patients [17-21]. However, fatigue levels in this outbreak cohort 
are self reported and a control group is lacking. Therefore these findings must be interpreted 
with extreme caution. Further studies are needed to evaluate long term symptoms and 
quality of life in Q fever patients in the Netherlands.
Using a commercially available IFA we observed a typical serological response to Coxiella 
burnetii infection with strikingly high levels of antibodies to both phase I and phase II 
antibodies. This serological response was characterized by an increase in antibody titers 
up to 3 months and a subsequent decrease in the following 9 months. The anti-phase I IgG 
kinetic, with a titer peak at 3 months, is different from available literature on IFA serological 
patterns in the follow-up of acute Q fever, that shows a rather slow and gradual increase of 
anti-phase I IgG antibodies [22,23]. The high proportion of Q fever patients in this cohort 
that received a beta-lactam antibiotic with no efficacy against Coxiella burnetii (38%) or no 
treatment at all (14%) could possibly account for this discrepancy. The CFT and the IFA test 
showed an identical serological pattern over time. Therefore, both tests might be useful for 
the follow-up of patients. Additional IFA should be performed when the CFT-titer is rising, to 
see the balance between anti-phase I and anti-phase II IgG antibodies. 
Although at the various timepoints there were patients with an anti-phase I IgG antibody 
titer of 1024 or more, suggesting chronic disease, none of these patients developed a clinical 
picture compatible with chronic Q fever. Furthermore, at follow-up, all these patients showed 
a spontaneous subsequent decline in anti-phase I IgG titers, which in the case of a possible 
chronic Q fever is highly unlikely, given the natural detrimental course of chronic disease if 
left untreated. 
For aiding in the diagnosis chronic Q fever, we used the well-established anti-phase I IgG 
antibody titer of  ≥ 800 [10]. Unfortunately, this cut-off value is based on a single center 
experience using a home made IFA test. Additional studies are urgently needed to compare 
both tests and to give cutt-off levels that can be used with commercially available IFA tests.
Q fever endocarditis may develop in up to 39% of patient with known pre-existing valvulopathy 
[24]. Even minor cardiac valve abnormalities might be a risk factor for Q fever endocarditis [7]. An 
active search for cardiac valvular abnormalities and serological surveillance following acute Q 
fever have been advocated to identify chronic Q fever in an early stage and to trigger prolonged 
prophylactic antibiotic treatment in case of even minor cardiac valvulopathy [7,8,25]. 
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No cases of chronic Q fever were observed during follow-up, despite the high incidence of 
minor valvulopathies found by screening echocardiography. Similar incidences of minor 
cardiac valvular abnormalities in the general population have been reported in large series 
[26,27]. For example, the prevalence of ‘trace’ mitral valve regurgitation is 40% and can 
therefore be considered to be a physiological phenomenon without clinical importance [12]. 
The prevalence of mitral valve prolaps and bicuspid aortic valve is estimated at 2-3% and 
circa 1% respectively [28,29]. The absolute risk of developing chronic Q fever for these minor 
valvulopathies remains unknown. The limited number of patients in this study does not 
allow to determine this risk, but it’s clear that the absolute risk, at least in the case of a minor 
mitral valve insufficiency, is likely to be small enough to withhold prolonged prophylactical 
antibiotic treatment and closely monitor serology during the  follow-up.
In the setting of the ongoing Q fever epidemic in the Netherlands that currently encompasses 
more than 3000 new Q fever patients, performing screening echocardiograms in all patients 
is costly [30]. Moreover, it is not likely that such a screening will detect cardiac valve 
abnormalities that in turn would influence clinical management. Therefore, we currently 
perform only serological and clinical follow-up after acute Q fever, omitting routine screening 
echocardiography. In other words, in the context of the large and continuous outbreak in 
the Netherlands, a pragmatic approach has been adopted for patients without known risk 
factors for chronic disease, consisting of closely serological monitoring for a period of one 
year (at 3, 6 and 12 months). Only when serological and/or clinical signs of chronic disease 
appear, is further investigation using PCR and echocardiography undertaken. In patients 
with known, pre-existing risk factors for chronic disease, including cardiac valvulopathy, 
decisions regarding follow-up and prophylactical antibiotic treatment are made in each 
individual case by a multidisciplinary team including a medical microbiologist, infectiologist 
and cardiologist. We realize that such a strategy can only be applied in countries with a low 
background prevalence of cardiac valvulopathies in the general population. Indeed in India, 
due to the high prevalence of rheumatic heart disease, Coxiella burnetii is responsible for 14% 
of culture negative endocarditis cases [31].
In conclusion, in the Dutch Q fever outbreak, an aspecific febrile illness with or without 
respiratory tract symptoms was the most common clinical presentation. Fatigue was 
present in 52% of patients at 6 months and dropped to 26% at one year follow-up. Using a 
commercially available IFA we observed a typical serological response to both phase I and 
phase II Coxiella burnetii antigens, characterized by an increase in antibody titers up to 3 
months and a subsequent decrease in the following 9 months. Screening echocardiography 
at baseline revealed cardiac valve abnormalities in 59% of patients investigated, with only 
7,6% having a clinically significant valvulopathy. None of the patients progressed to chronic 
disease. Baseline screening echocardiography is no longer part of the standard work-up of Q 
fever patients the Netherlands.
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Abstract
The value of echocardiographic screening for cardiac valvular abnormalities of every acute Q fever 
patient and administration of longterm prophylactic antibiotic treatment in case of any, be it trivial or 
clinically significant, valvular defect has not been prospectively validated in an unselected population 
of Q fever patients.
A high prevalence of clinically insignificant valvular defects was found in al large group of Q fever 
patients from both the 2007 and 2008 cohort (n=134), but no patients developed chronic Q fever. 
By contrast with existing publications, these data indicate a low risk of progression to Q fever 
endocarditis. This contrasting result may be explained by selection bias and lack of specification of 
valvular defect severity in published retrospective research. 
In the setting of a massive Q fever outbreak, this raises the question whether the harm of low-treshold 
administration of long-term antibiotic prophylaxis for mild valvular defects outweighs the benefit. In 
addition, the associated health-care costs of such a follow-up strategy on a large scale are substantial.
Prevention of Q fever endocarditis 
Ch
ap
te
r 4
45
Prevention of Q fever endocarditis
Confronted with more than 4000 human Q fever cases in the Netherlands since 2007, we 
appreciated the milestone article of Matthieu Million and colleagues’ paper about Q fever 
endocarditis [1]. 
Since cardiac valvular disease is regarded as a major risk factor for this rare but potentially fatal 
complication, the investigators emphasise their follow-up strategy: systematic screening for 
cardiac valvular abnormalities of every acute Q fever patient and administration of longterm 
prophylactic antibiotic treatment in case of any, be it trivial or clinically significant, valvular 
defect [2]. 
However, this follow-up strategy has never been prospectively validated in an unselected 
population of patients with Q fever. We present here the outcome of 134 Dutch patients 
with Q fever from the 2007 and 2008 outbreaks, who had screening echocardiography and 
prospective serological follow-up for 1 year (tables 1 and 2). None of the patients received 
antibiotic prophylaxis and none developed clinical or serological signs of Q fever endocarditis. 
Additionally, none had developed clinical signs suggestive of chronic disease during the past 
2 years. 
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* Multiple predisposing valvular diseases are possible for a patient 
** Trace regurgitation was not considered a degenerative valvulopathy 
 
Table 1. Characteristics of patients and echocardiographic findings
By contrast with existing publications, our data indicate a very low risk of progression to Q 
fever endocarditis. This contrasting result may be explained by selection bias and lack of 
specification of valvular defect severity in published retrospective research [3,4]. 
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In these studies, the risk of endocarditis in patients with acute Q fever and pre-existing 
cardiac valve defects was estimated to be 39%, but many of the included patients had 
prosthetic valves [3]. Million and colleagues [1] describe a highly selective cohort with valve 
defects mostly caused by rheumatic fever (30%, about half of all specified valvular disease), 
a disorder that is rare in most developed countries. Furthermore, 30% of their patients had 
infected prosthetic valves [1]. Degenerative valvular disease was present in only 5% [1] 
whereas this type of valvular defect is highly prevalent in the general population (22% in 
our study). Minor, clinically insignificant valvular disease (trace and mild defects) has a high 
prevalence in any unselected population [5]. In our study, these defects were not associated 
with development of chronic disease. 
In our setting, the harm of low-threshold administration of long-term antibiotic prophylaxis 
might therefore outweigh the benefit. Additionally, the associated healthcare costs of this 
follow-up strategy on a large scale are substantial. Screening echocardiography is therefore 
no longer undertaken in patients with acute Q fever in the Netherlands.
We declare that we have no conflicts of interest. We thank R Besselink and A Olde-Loohuis for 
clinical follow-up, G Weers and A Horrevorts for serological testing, C Wijkmans for collecting 
data, and J A Visser for providing the  echocardiographic tests.
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Table 2. Valvulopathy at screening echocardiography***
trace mild moderate severe
Mitral regurgitation 50 15 7 2
Aortic regurgitation 9 10 4 0
Aortic stenosis 0 2 0 0
Mitral stenosis 0 0 1 0
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Abstract
Background
Q fever is a zoonosis caused by the obligate intracellular bacterium Coxiella burnetii. The two long-
term complications, after primary infection, are chronic Q fever in 1% of patients, and a chronic fatigue 
syndrome in 10–20%. However, the existence of a protracted decreased health status after Q fever 
remains controversial.
Aim
To determine the health status of the patients of the Q fever outbreak in The Netherlands in 2007, 1 year 
after primary infection.
Design
Cross-sectional case–control study.
Methods
Health status of the patients from the 2007 Dutch Q fever outbreak was compared to age-, seks and 
geographically matched and Q fever seronegative controls. Health status of both patients and controls 
was assessed with the Nijmegen Clinical Screening Instrument (NCSI).
Results
Fifty-four Q fever patients provided 34 years of age- and sex-matched controls from the same 
neighbourhood. Eleven controls had positive Q fever serology and were excluded. Q fever patients 
had significantly more problems on the subdomains of symptoms and functional impairment. Overall 
quality of life was decreased in both patients and controls, 59% vs. 39%, respectively, ns). Severe fatigue 
levels were present in 52% of patients vs. 26% in controls (P < 0.05).
Conclusion
These data support a sustained decrease in many aspects of health status in Q fever patients in The 
Netherlands, 1 year after primary infection.
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Introduction
Q fever is a zoonosis caused by the obligate intracellular bacterium Coxiella burnetii [1]. In 
its acute form, Q fever generally presents as a mild flu-like syndrome, atypical pneumonia 
or hepatitis [1,2]. After primary infection, approximately 1% of patients develop chronic Q 
fever, mainly as endocarditis in patients with pre-existing cardiac valvulopathies [1,3]. In 
recent years, research groups have drawn attention to another, less known, chronic sequel 
to primary Q fever, which takes the form of a debilitating chronic fatigue syndrome lasting 
more than 6 months in up to circa 20% of patients [4-9]. However, despite these reports on 
post Q fever fatigue, the existence of a ‘post Q fever fatigue syndrome’ or QFS as a distinct 
clinicopathological entity remains controversial, especially in France and the US [1,10]. In 
2007, a goat-farming related Q fever outbreak of 73 cases was identified in the rural town 
of Herpen, the Netherlands [11]. Since then, an ongoing Q fever endemic has produced the 
Dutch province of North-Brabant as the currently most hyperendemic region in the world 
with more than 3000 acute Q fever cases in 2008 and 2009 [12,13]. No data exist on the impact 
on the long term impact on health status after acute Q fever in the Netherlands. The aim of 
the present study was to determine the health status of the patients of the Q fever outbreak 
in the Netherlands in 2007, one year after primary Q fever infection.
Methods
Patients
All patients from the Q fever outbreak cluster in Herpen (n=73) were asked to participate. A 
case of acute Q fever was defined as any inhabitant of the outbreak cluster area who presented 
with compatible clinical symptoms and a positive serology defined by immunofluorescence 
assay (IFA) (Focus diagnostics). Positive serology was defined as both anti-phase II IgM and 
anti-phase II IgG antibodies with a 1:64 or greater dilution or a seroconversion consisting of a 
fourfold increase of anti-Phase II IgG titer during follow-up. All Q fever patients were followed 
up serologically for a period of one year for antibodies against both Phase I and Phase II 
antigens, to exclude progression to chronic infection. As controls, Q fever patients were asked 
to bring along an age and sex matched control subject from their neighbourhood, without a 
history of Q fever. Control subjects had to be age (plus or minus 10 years) and sex matched 
to the patient. Control subjects were serologically tested for Coxiella burnetii antibodies 
using IFA. Positive serological findings of Q fever excluded controls from the primary analysis. 
Documentation on actual significant comorbidity was available for all participants. All 
patients provided written informed-consent. The study was approved by the local Ethical 
Board for Human Research. (Commissie Mensgebonden Onderzoek file-nr.: 2008/192, ABR 
nr.: NL24404.091.08)
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Study design
The health status of the patients from the 2007 Q fever outbreak was compared to age-, 
sex- and geographically matched controls. Health status of both patients and controls was 
assessed with the Nijmegen Clinical Screening Instrument (NCSI) 1 year after the initial Q 
fever infection. 
The Nijmegen Clinical Screening Instrument (NCSI)
In the literature, health status is defined as covering physiological functioning, symptoms, 
functional impairment in daily life, and quality of life as main domains [14,15]. These domains 
were shown empirically to be subdivided into many independent sub-domains [16]. The 
NCSI is an empirically composed battery of well validated instruments that enable a detailed 
measurement of these sub-domains of health status [17]. See table 1 for the tests and 
instruments by which the sub-domains of Health Status were measured. In the present study, 
the NCSI covers 8 sub-domains of the main domains ‘symptoms’, ‘functional impairment’ 
and ‘quality of life’. The clinical meaning of these main domains is given hereafter.
Main domain Subjective Symptoms
The sub-domain Subjective Symptoms represents the patient’s overall burden of dyspnea 
and experienced dyspnea during activities. The sub-domain Dyspnea Emotions embodies 
the level of frustration and anxiety a person experiences when dyspnoeic.
Main domain Functional Impairment
The sub-domain Behavioural Impairment represents the extent to which a person cannot 
perform specific and concrete activities, with respect to ambulation and activities at home, 
as a result of having the disease. The sub-domain Subjective Impairment represents the 
experienced degree of impairment.
Main domain Quality Of Life
The sub-domain General QoL covers mood and satisfaction with  life as a whole. The sub-
domain HRQoL represents satisfaction with physical functioning and confidence in the 
future. The sub-domain Satisfaction Relations represents the satisfaction with (or absence 
of) the relationships with spouse and others. 
The NCSI provides normative data for each sub-domain; increasing scores indicating normal 
functioning, mild problems or severe problems.
Statistical analysis
All quantitative data are presented as mean ± se if normally distributed, otherwise median 
values (with range) are reported. Testing for differences between patients and controls was 
performed by Pearson’s Chi2 or Mann-Whitney test when appropriate. Statistical significance 
is set at a p< 0.05. Data were analyzed with SPSS 14. 
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functioning, mild problems or severe problems. 
 
Statistical analysis 
All quantitative data are presented as mean ± se if normally distributed, otherwise median 
values (with range) are reported. Testing for differences between patients and controls was 
performed by Pearson’s Chi2 or Mann-Whitney test when appropriate. Statistical significance 
is set at a p< 0.05. Data were analyzed with SPSS 14.  
 
Table 1. Main domains and subdomains of the NCSI, their corresponding instruments and scales [18]. 
 
Results 
Results
A total of 54 of the 73 (74%) Q fever patients from the 2007 Herpen outbreak agreed to 
participate. Thirty-four of these patients provided an age and sex-matched control from 
the same neighbourhood. Eleven of these controls had positive Q fever serology and were 
excluded, leaving 23 seronegative controls for comparison. Characteristics of the study and 
seronegative control subjects are given in table 2. Patients and controls proved to be well 
matched for age, sex, pre-existing comorbidity and smoking status. 
Table 1. Main domains and subdomains of the NCSI, their corresponding instruments and scales [18]
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group 
 
*Pearson Chi-Square, $mann-whitney test 
 
Results on the sub-domains of the NCSI on a group level are provided in table 3. Q fever 
patients had significantly higher scores on all sub-domains of ‘symptoms’ (subjective 
pulmonary symptoms, dyspnea emotions, fatigue), ‘functional impairment’ (subjective 
impairment, behavioural impairment) and ‘satisfaction with relations’. With respect to the 
main domain ‘quality of life’, there was a non-significant trend towards more problematic (i.e. 
higher) scores on the sub-domains ‘general quality of life’ (p = 0,09) and health related 
quality of life’ (p = 0,073). In figure 1 results are presented on an individual level by the 
percentages of patients and controls scoring in the range of normal, mild, or severe 
problems. Fatigue scores of Q fever patients were abnormal (score: mild or severe) in 74% 
vs 48% in controls. Severe fatigue levels were present in 52% of patients vs. 26% in 
controls. Overall quality of life was decreased in a substantial number of patients and  
Table 2. Patient characteristics expressed in number (%) unless stated otherwise of the patient group, and 
control group
Results on the sub-domains of the NCSI on a group level are provided in table 3. Q fever 
patients had significantly higher scores on all sub-domains of ‘symptoms’ (subjective 
pulmonary symptoms, dyspnea emotions, fatigue), ‘functional impairment’ (subjective 
impairment, behavioural impairment) and ‘satisfaction with relations’. With respect to the 
main domain ‘quality of life’, ther  was a non- ignificant trend towards more problematic (i.e. 
higher) scores on the sub-domains ‘general quality of life’ (p = 0,09) and health related quality 
of life’ (p = 0,073). In figure 1 results are presented on an individual level by the percentages of 
patients and controls scoring in the range of normal, mild, or severe problems. Fatigue scores 
of Q fever patients were abnormal (score: mild or severe) in 74% vs 48% in controls. Severe 
fatigue levels were present in 52% of patients vs. 26% in controls. Overall quality of life was 
d cr ased in a substantial number of patients and controls, but not significantly different 
between the two groups (Q fever patients 59% vs. controls 39%, ns). In figure 2 the percentage 
of patients and controls (y-axis) is given as a function of the number of sub-domains in which 
these patients and controls experience severe problems (x-axis) . In addition to the primary 
data analysis, we compared NCSI scores of the excluded seropositive controls (n=11) with 
the scores of seronegative control subjects (n=23). The NCSI scores of seropositive- and 
seronegative controls were not statistically different in all 8 measured sub-domains of health 
status (p > 0,05 for all sub-domains).
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Figure 1. Percentages of mild and severe problems for each subdomain of the NCSI for the patient and control 
group (*p<0,05). 
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Figure 2. Frequency distribution of numbers of subdomains with severe problems in patients and controls.
Discussion
One year after primary infection, Q fever patients from the 2007 Herpen outbreak had a 
significantly lower health status in many sub-domains of the main domains ‘symptoms’ and 
‘functional impairment’, when compared to age-, sex- and geographically-matched controls. 
Overall quality of life and health-related quality of life were significantly decreased in both 
patients and controls. Furthermore, on an individual level, patients had severe problems in 
more sub-domains than controls. Our findings lend support to the notion of a protracted 
reconvalescence phase after Q fever associated with decreased health status in many aspects.
We found remarkably high clinically relevant (=severe) fatigue levels in roughly half (52%) of 
the Q fever patients one year after infection. In two separate case control studies published 
as letters the editor in the Lancet in 1996, Marmion et al. and Ayres et al. reported a syndrome 
of protracted fatigue and debility in Q fever patients for more than 5 years after primary 
infection with similar fatigue levels (67% (n=39) and 66% (n=71) respectively) [4,5]. Five- and 
10-year follow-up of the large Q fever outbreak in the West Midlands, UK, also showed similar 
levels of chronic fatigue [6,7]. Dubbed the post Q fever fatigue syndrome (QFS), this protracted 
	 51 
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fatigue state shares common features with the chronic fatigue syndromes following other 
(viral) pathogens such as Epstein-Barr virus and Ross River virus [9]. 
Although there was a significantly higher fatigue level in Q fever patients, the abnormally 
high fatigue level and low overall quality of life and health-related quality of life of the control 
group is striking. We postulate two explanations for this. First, the level of co-morbidity in 
this study is around 40%, which could partly account for the overall high scores on the NCSI 
sub-domains. Second, the original normal values for NCSI sub-domain scores were derived 
from healthy control subjects with normal pulmonary function tests. As these test were not 
available in the present study and given the significant smoking history equally present in 
patients and controls, undocumented pre-existing pulmonary morbidity may also have 
increased NCSI sub-domain scores in both groups.
Remarkably, NCSI scores from controls without a clinical history of Q fever but with serological 
evidence of exposure to Coxiella burnetii (and thus excluded from the primary analysis), were 
not statistically different from seronegative controls, suggesting that clinical expression of 
acute Q fever infection is an essential factor in the subsequent sustained decrease in health 
status. Severity of initial illness previously indeed has been shown to be the best predictor 
of subsequent development of a post-infective fatigue syndrome in both viral and non-viral 
pathogens, including Q fever [9]. Moreover, the same genetic polymorphisms in cytokine 
genes with critical roles in the inflammatory reponse to infection, underpin both the severity 
of the acute sickness and the average time to recovery across varied infections, including Q 
fever [19].   
There are obvious difficulties with the credibility of QFS as a distinct clinico-pathological 
entity, as confounding factors such as financial compensation or insurance benefits 
following the acute sickness can be held responsible for the symptomatology and associated 
reduced quality of life. However, both the West Midlands outbreak mentioned earlier and 
the currently described Dutch outbreak were non-occupational and no litigation for financial 
compensation was pursued. A QFS diagnosis relies solely on the patient’s own account of 
symptoms. In clinical practice, QFS patients remain indistinguishable from patients with 
a complete recovery after primary infection with Coxiella burnetii, as they do not meet the 
criteria for chronic Q fever infection: anti-phase I IgG titers are < 800 and appropriate cultures 
of the patients blood or tissues show no viable bacteria. Recently, an elegant new paradigm 
of persistence of Coxiella antigenic non-viable cell residues after primary infection in 
interaction with immunogenetic polymorphisms in the host has been put forward to better 
explain the chronic sequelae of acute Q fever, including QFS [20]. The importance of genetic 
host factors in QFS is supported by research done by Kerr et al. in the United Kingdom. 
They found significant differences in expression of 88 human genes, notably with a high 
proportion of genes involved in the immune response and infection, between patients with 
idiopathic chronic fatigue syndrome and normal controls. Remarkably, QFS patients were 
found to have similar patterns of gene expression to patients with idiopathic chronic fatigue 
syndrome [21,22]. 
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Although our data support a decrease in many aspects of health status in many Q fever 
patients, some considerations have to be taken into account. First of all, patient numbers are 
small. However, Q fever patients were optimally matched, including serological testing in the 
controls. Furthermore, despite the small numbers, a statistically significant difference was 
found in 6 of the 8 tested sub-domains of the NCSI, supporting the notion of a rather large 
difference in health status between patients and controls. Second, the NCSI has proved to 
be a useful tool in assessing health status for use in research and care, but has mostly been 
applied in COPD patients. We used the NCSI in the setting of post-infectious health status 
assessment for the first time. Nevertheless, the various (parts of) questionnaires used to 
compile the NCSI function in their original and unaltered form. These generic questionnaires 
are not specified to assess only pulmonary disease and assess the different sub-domains 
of health status in the exact same way these instruments were originally designed and 
validated for.  Moreover, the NCSI can be used by the clinician as an excellent tool to identify 
and monitor health status in its various sub-domains and can even guide therapeutic 
(psychological) interventions. 
In conclusion, these data support a sustained decrease in health status in Q fever patients in 
the Netherlands, one year after primary infection. With more than 3000 new Q fever patients 
in the last 2 years in the setting of the ongoing Dutch Q fever epidemic, these are the first 
clinical data indicating a major long-term burden of the disease in the years to come. 
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Abstract
A significant proportion of Q fever patients from the first Dutch Q fever outbreak in 2007 showed 
impairment in health status up to 1 year after infection. Interested in whether this decrease in health 
status persisted, we set out to determine the health status in the same cohort of patients, 4 years after 
primary infection and to compare health status scores on an individual patient’s level between 1 and 
4 years follow-up. Health status was assessed with the Nijmegen Clinical Screening Instrument (NCSI). 
Patients were serologically tested to exclude patients with possible, probable or proven chronic Q 
fever. Results on the sub-domains of the NCSI on a group level [2008 (n=54) and 2011 (n=46)] showed 
a persistent significant percentage of patients exhibiting clinically relevant (‘severe’) scores for all sub-
domains of the NCSI. After 4 years, undue fatigue was present in 46% and exactly half of all patients 
experienced a severely impaired general quality of life. Patients with NCSI scores available in both 2008 
and 2011 (n=37) showed no difference in all sub-domain scores, except for a small decrease in dyspnea 
emotions in 2011. In this group, a significant proportion of patients either improved or worsened in 
one or more sub-domains of health status. We conclude that on a group level, health status of Q fever 
patients remained impaired 4 years after primary infection. On an individual patient’s level, health 
status may change.
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Introduction
Q fever, an ubiquitous zoonosis caused by the intracellular bacterium Coxiella burnetii, 
emerged as a human pathogen in The Netherlands in 2007 [1]. Successive annual outbreaks 
linked to intensified goat farming have amounted to more than 4000 notified and a further 
estimated 44000 unnotified human cases, the majority of which occurred in the province 
of Noord-Brabant in the south of the Netherlands [2]. Following extensive governmental 
measures including restrictions on manure trafficking, vaccination and culling of dairy goats 
and sheep starting in 2010, the rate of acute human Q fever cases fell markedly. However, 
since then chronic Q fever has remained a significant clinical problem [3]. Accordingly, 
research efforts have shifted in recent years from management of acute disease to the long 
term sequelae of Q fever; chronic Q fever (vascular infection, endocarditis) and the Q fever 
fatigue syndrome (QFS) [4].
Early reports after the first outbreaks in 2007 and 2008 showed persistent symptomatology, 
especially fatigue, and a decreased health status of Q fever patients for a follow-up period 
of 12-26 months [5,6]. Health status scores of patients at 12 months versus 17-26 months 
follow-up did not differ significantly, suggesting a long term persistence of impaired health 
status of equal severity level after one year. The original small studies from Australia and 
England suggest persistent symptomatology and decreased health status can persist for 5-10 
years [7,8].
For the patients of the Dutch Q fever outbreaks, it remains unknown whether impaired 
health status and symptomatology persist or can change after 1-2 years. In addition to the 
evaluation of long term health status on a group level, changes in health status of individual 
patients have not been studied before.
The first aim of this study was to determine the health status of patients from the first Q fever 
outbreak in the Netherlands 4 years after primary infection. Second aim was to compare 
health status scores on an individual patient’s level between 1 and 4 years follow-up, for 
those patients for whom data were available at both time points.
Methods
Study design and population
Health status of patients from the 2007 Q fever outbreak was assessed with the Nijmegen 
Clinical Screening Instrument (NCSI), 4 year after the initial Q fever infection. The same 
questionnaire (NCSI) was used in an earlier assessment of health status of patients from 
the Herpen outbreak cluster at one year follow-up [5]. This allows for direct comparisons 
of scores on an individual patient level between time points 1 and 4 years follow-up. All 
surviving patients from the 2007 outbreak followed up in the GP’s practice in Herpen were 
asked to participate [9]. Patients who did not respond to the initial invitation were contacted 
by mail and a single telephone call.
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Clinical evaluation and questionnaire
Evaluation of participants included a complete history and physical examination by their 
own physician, completion of the NCSI questionnaire and a single venous blood sampling 
for serological testing to exclude patients with possible, probable or proven chronic Q fever. 
Serological testing consisted of the determination of IFA phase I IgG (Focus diagnostics, 
Cypress, CA, USA) antibodies. Following the diagnostic criteria of the Dutch Q fever Consensus 
Group, an IgG phase I of 1024 or more excluded patients from analysis [10]. 
All patients provided written informed consent. This study was approved by the local Ethical 
Board for Human Research. (Commissie Mensgebonden Onderzoek file-nr.: 2008/192, ABR 
nr.: NL24404.091.08, amendment dd 3 September 2010)
Questionnaire: the Nijmegen Clinical Screening Instrument (NCSI) 
The NCSI has been used in previous studies assessing health status after Q fever infection 
[5, 6, 11-13]. It is based on an empirical definition of health status, covering ‘physiological 
functioning’, ‘symptoms’, ‘functional impairment in daily life’, and ‘quality of life’ as main 
domains. These domains are in turn subdivided into many independent sub-domains. The 
NCSI is an empirically composed battery of well validated instruments that enable a detailed 
measurement of these sub-domains of health status [14]. The NCSI provides normative 
data for each individual sub-domain; increasing scores indicating normal functioning, 
mild problems or severe problems. We excluded the domain ‘physiological function’ from 
the NCSI questionnaire as patients did not perform pulmonary function tests. In this study 
we measured the same main domains as in 2008; ‘symptoms’, ‘functional impairment’ 
and ‘quality of life’. The corresponding sub-domains are ‘subjective symptoms’, ‘dyspnea 
emotions*’, ‘fatigue’, ‘behavioral impairment’, ‘subjective impairment’, ‘general quality of life’, 
‘health related quality of life’ and ‘satisfaction with relations’ [5]. (The subdomain subjective 
symptoms represent the patient’s overall burden of dyspnea and experienced dyspnea 
during activities. The subdomain ‘dyspnea emotions’ embodies the level of frustration and 
anxiety a person experiences when dyspnoeic.)
Statistical analysis
All quantitative data are presented as mean plus or minus standard error if normally 
distributed, otherwise median values (with range) are reported. Testing for differences 
between patients in 2008 and 2011 was performed by Pearson’s Chi2 or Mann-Whitney test 
when appropriate. Statistical significance was set at a p< 0.05. Data were analyzed with SPSS 
v. 14 (SPSS Inc., USA).
Results
A total of 47 (57%) of 82 surviving Q fever patients from the 2007 outbreak who were followed up 
in the Herpen GP’s practice, agreed to participate and were included. All patients underwent 
clinical evaluation, provided a completed NCSI questionnaire and a blood sample. One of 
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Statistical analysis 
All quantitative data are presented as mean plus or minus standard error if normally 
distributed, otherwise median values (with range) are reported. Testing for differences 
between patients in 2008 and 2011 was performed by Pearson’s Chi2 or Mann-Whitney test 
when appropriate. Statistical significance was set at a p< 0.05. Data were analyzed with 
SPSS v. 14 (SPSS Inc., USA). 
 
Results 
A total of 47 (57%) of 82 surviving Q fever patients from the 2007 outbreak who were 
followed up in the Herpen GP’s practice, agreed to participate and were included. All 
patients underwent clinical evaluation, provided a completed NCSI questionnaire and a 
blood sample. One of the patients had a phase I IgG of 1024, indicating possible, probable 
or proven chronic Q fever, and was referred to an infectious diseases specialist for 
evaluation, leaving 46 patients for analysis. For 37 patients the NCSI scores were available at 
both the 1 and 4 year follow-up, allowing for longitudinal comparison of health status at the 
individual patient’s level.  
In table 1, patient characteristics of this study population (n=46) are given for comparison 
with the data on the patient group assessed in 2008 (n=54).  
 
Table 1. Patient characteristics expressed in number (%) unless stated otherwise  
# see reference [5] 
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Table 2. Percentage of patients scoring normal, elevated or severe scores on the NCSI in 2008 (n=54) and 2011 
(n=46). 
 
Table 3. Comparison of NCSI scores for all sub-domains* on an individual patient’s level between 2008 and 2011 
(N=37). * the higher the score, the more problematic, for reference values for all subdomains see reference [14] 
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(n=46).
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Table 4. Percentages of patients whose NCSI scores improved, remained equal or worsened* on an individual 
patient’s level, between follow-up time points 2008 and 2011 (n=37). 
* Differences between scores in 2008 and 2011 were calculated as follows:         (Score 2008 – score 2011 ) / sd 
2008.  A difference on a subdomain score of < -0.5 corresponds with significant improvement; a score of > -0.5 and 
< 0.5 means no significant change and a score of > 0.5 corresponds to worsening of health status in that 
subdomain. 
 
Results on the sub-domains of the NCSI on a group level (table 2) for 2008 (n=54) and 2011 
(n=46) show a persistent significant percentage of patients exhibiting clinically relevant 
(‘severe’) scores for all sub-domains of the NCSI. No significant differences were found 
between patients with or without co-morbidities on any of the sub-domains of the NCSI. 
Overall, severe subjective symptoms were present in 35% of patients. After 4 years, undue 
fatigue was present in 46% (52% after 1 year) and exactly half of all patients experienced a 
severely impaired general quality of life.  
Comparison of sub-domains for patients with NCSI scores available in both 2008 and 2011 
(n=37, table 3.) showed no difference in all sub-domain scores, except for a small but 
statistically significant decrease in dyspnoea emotions.  
Table 4. Percentages of patients whose NCSI scores improved, remained equal or worsened* on an individual 
patient’s level, between follow-up time points 2008 and 2011 (n=37).
* Differences between scores in 2008 and 2011 were calculated as follows:         (Score 2008 – score 2011 ) / sd 
2008.  A difference on a subdomain score of < -0.5 corresponds with significant improvement; a score of > -0.5 
and < 0.5 means no significant change and a score of > 0.5 corresponds to worsening of health status in that 
subdomain.
Results on the sub-domains of the NCSI on a group level (table 2) for 2008 (n=54) and 2011 
(n=46) show a persistent significant percentage of patients exhibiting clinically relevant 
(‘severe’) scores for all sub-domains of the NCSI. No significant differences were found 
between patients with or without co-morbidities on any of the sub-domains of the NCSI. 
Overall, severe subjective symptoms were present in 35% of patients. After 4 years, undue 
fatigue was present in 46% (52% after 1 year) and exactly half of all patients experienced a 
severely impaired general quality of life. 
Comparison of sub-domains for patients with NCSI scores available in both 2008 and 
2011 (n=37, table 3.) showed no difference in all sub-domain scores, except for a small but 
statistically significant decrease in dyspnoea emotions. 
Table 4. shows the dynamics of NCSI scores on an individual patient’s level, as percentages 
of pati nt  who e scores either i proved, remained equal or worsened between 2008 and 
2011. A significant proportion of all individual Q fever patients either improved or worsened 
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in one or more sub-domains of health status. Fatigue scores improved in about one-third of 
patients, but worsened in one in five (21%). More than 30% of patients showed significant 
improvement in the subdomains of ‘fatigue’, ‘subjective impairment’ and ‘health related 
quality of life’, but these improvements were cancelled out on a group level by patients with 
worsening scores.
Discussion
Persistence of impairment in many subdomains of health status after 4 years in the majority 
of affected Q fever patients is marked, and suggests an absence of further dynamics in 
symptomatology after 1 year. These findings tally with earlier research in England, Australia 
and Canada, on very long term sequelae post Q fever infection, reporting increased 
symptomatology including similar levels of fatigue up to 10 years after primary infection [15-
17]. A further finding is that on an individual patient level, although the majority remains 
equally impaired, patients can improve or worsen on an individual basis in one or more 
subdomains of health status between 1 and 4 years. 
This study has several strengths and weaknesses that need to be addressed. This is the first 
report on longitudinal long term health status of Q fever patients in the Netherlands for more 
than 2 years follow-up. The availability of detailed health status data at follow-up points 1 
year and 4 years for the same patients allowed for comparison on an individual patient’s level, 
a feature that has not been studied before. Also, serology was performed to exclude chronic 
disease. As the background prevalence of serological evidence of past Q fever infection in 
endemic regions in the Netherlands reaches up to 15%  and chronic Q fever can develop in 
1-5% of Q fever patients, this is highly relevant [18]. 
The limited patient number in this study is a weakness, and precludes generalisation of the 
obtained results to the entire Dutch Q fever outbreak population. The small patient number 
is largely due to the fact that the study-cohort comprised the very first, local group of Q fever 
patients in the Netherlands from the rural town of Herpen, in the province of Noord-Brabant 
[9]. Furthermore, the absence of a proper Q fever negative control group at the 2011 time 
point does not allow for an estimation of how much impairment of health status is actually 
directly caused by the primary infection with Coxiella burnetii. 
This study provides further evidence for persistent symptomatology and long term decreased 
health status of Q fever patients in the Netherlands. Research groups in England, Australia 
and Canada have similarly found consistent and clear decreased long term health status 
outcomes in Q fever patients, using various/different questionnaires and study methods [15-
17]. The acknowledgement and acceptance of a protracted fatigued state following acute 
Q fever in about 20% of patients, sometimes designated the post Q fever fatigue syndrome 
(PQFS), however, is not universal [19,20]. The main reasons for this reluctance seem to be 
the incompletely understood pathophysiology of PQFS, the absence of a diagnostic test 
and possibly, fear of patient’s financial compensation claims. Moreover, post-infectious 
protracted fatigue states have been reported for several other bacterial and viral pathogens 
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such as Bartonella, Legionella, Epstein Barr virus, Cytomegalovirus and West Nile Virus [21, 
22]. A recent Dutch study, using the NCSI and the Short Form 36 (SF36), compared the health 
status of 309 Q fever patients and 190 patients with Legionnaires’ disease and found severe 
impairment of various health status subdomains including fatigue for both diseases 1 year 
after onset of illness [11]. Another smaller study from the Netherlands compared 50 patients 
with a lower respiratory tract infection (LRTI) caused by Q fever with 32 non Q fever LRTI 
patients with a follow up period of 10 to 19 months. With the exception of the sub-domain 
‘subjective pulmonary symptoms’, no difference was observed in health status for all 
other measured subdomains using the NCSI [12]. Interestingly, as in our study, significant 
proportions of Q fever patients experienced severe fatigue (40%) and severely impaired 
general quality of life (40%).  
There are numerous studies probing the underlying pathophysiology of PQFS that show 
significant differences between Q fever patients with and without PQFS with regard to gene 
expression [23-25], serum cytokine levels [26] and PBMC cytokine release patterns after 
stimulation with Coxiella burnetii antigens [26,27]. However, there are several shortcomings 
that impede a thorough interpretation and unifying concept of PQFS pathophysioloy; a lack of 
a clear definition of PQFS, small patient numbers and different lab techniques and protocols 
that do not allow for ready comparison and validation of obtained results. Recently, a new 
unifying paradigm has been put forward for PQFS, postulating PQFS symptomatology to be 
underpinned by the interaction of persistent Coxiella specific non-viable cell residues with 
immunogenetic polymorphisms in the host [28,29].
Moreover, there is no validated evidence based treament for PQFS. To address this last 
issue, a large randomised placebo-controlled prospective clinical trial is underway in The 
Netherlands assessing the efficacy of longterm treatment with doxycycline and cognitive 
behavioral therapy in PQFS patients [30].
In conclusion, these data support an overall sustained impaired health status of Q fever 
patients in the Netherlands 4 years after primary infection. A minority of Q fever patients with 
impaired health status in 2008 showed improvement in various subdomains of health status 
by 2011, but on a group level this effect was canceled out by patients with worsening scores.
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Abstract
Definitively establishing a clinical diagnosis of chronic Q fever remains challenging, as the diagnostic 
performance of both conventional serological tests and PCR is limited. Given the importance of an early 
diagnosis of chronic Q fever, there is a need for a reliable diagnostic test. 
We developed an enzymelinked immunospot assay to measure Coxiella burnetii (C. burnetii)-specific 
T-cell responses (Coxiella ELISPOT) to both phase I and phase II antigens and tested convalescent Q 
fever patients (without chronic disease, n = 9) and patients with an established diagnosis of chronic 
Q fever (n = 3). The Coxiella ELISPOT adequately identified convalescent Q fever patients from healthy 
controls by demonstrating C. burnetii-specific T-cell interferon-c production to both phase I and phase 
II antigens. Compared to convalescent Q fever patients, chronic Q fever patients showed a distinct 
Coxiella ELISPOT profile characterized by a much higher spot count for both phase I and phase II (18-
fold for phase II, 8-fold higher for phase I) and a consistent shift towards more phase I reactivity. 
The diagnostic potential of the Coxiella ELISPOT is promising and warrants further investigation.
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Introduction
In the Netherlands, annual Q fever outbreaks associated with goat farming have amounted to 
more than 4000 new human Q fever cases since 2007 (Delsing et al., 2010). With an expected 
2–5% of patients developing chronic Q fever, clinicians now increasingly face the challenges 
in accurately diagnosing this rare but potentially fatal complication of Coxiella burnetii (C. 
burnetii) infection (Delsing et al., 2010; Frankel et al., 2011). The main clinical manifestations 
of chronic disease following the Dutch outbreaks are infection of vascular aneurysms and 
prostheses, closely followed by endocarditis (Delsing et al., 2010). In routine clinical practice, 
definitively establishing a diagnosis of chronic Q fever diagnosis is challenging and relies 
heavily on the demonstration of a vigorous humoral immune response to the antigenic 
phase I C. burnetii, as evidenced by high levels of phase I IgG antibodies (Frankel et al., 2011). 
In conjunction with suggestive serology, a positive serum PCR for Coxiella DNA is considered 
diagnostic for chronic disease (Fenollar et al., 2004; Wegdam-Blans et al., 2011). This poses 
an important clinical problem, as the performance of serological tests and PCR is limited in 
both establishing and excluding a diagnosis of chronic disease. A possible explanation for 
the underperformance of current serological assays may be the fact that these tests only 
reflect the host’s humoral immunity, whereas the most relevant immunological response to 
chronic infection with the obligate intracellular C. burnetii is first and foremost cellmediated 
(Andoh et al., 2007; Marmion et al., 2009). 
Given the importance of an early diagnosis of chronic Q fever timely prompting long-term 
antibiotics and/or surgical intervention, testing a patient’s cellular rather than humoral 
immunological response to C. burnetii might be a more reliable tool for diagnosing chronic 
Q fever in a clinical setting. 
A recently developed paradigm indeed proposes clinical outcome after C. burnetii infection as 
a function of host immunity/pathogen interaction with a strong emphasis on dysfunctional 
cellular immunity (Marmion et al., 2009).
T-cells and their associated cytokines, interferon-γ (IFN-γ) being the most potent, have 
a pivotal role in dealing with primary infection and subsequent clearance or control of 
intracellular pathogens such as Mycobacterium tuberculosis, Legionella pneumophila, 
Chlamydophila and C. burnetii (Andoh et al., 2007). The long-term clinical outcome of Q fever 
might, therefore, be better characterized by measuring the host’s C. burnetii-specific T-cell 
response. IFN-γ release assays (IGRA) such as ELISPOT can detect the IFN-γ production by 
antigen-specific T-cells ex vivo at an individual cell level. In tuberculosis, IFN-γ based tests 
are superior to tuberculin skin testing in detecting patients with latent infection and are 
better predictors of subsequent development of active disease (Santín Cerezales & Benítez, 
2011). We hypothesize that different Q fever clinical outcomes (nonchronic past infection and 
chronic disease) are similarly associated with marked differences in a patient’s C. burnetii 
antigenspecific T-cell IFN-γ production.
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Aim
The first aim of this study was to develop an enzymelinked immunospot assay to measure C. 
burnetii-specific T-cell responses (Coxiella ELISPOT) in convalescent Q fever patients (without 
any evidence of chronic Q fever). The second aim was to test the Coxiella ELISPOT in patients 
with an established diagnosis of chronic Q fever.
Materials and methods
Coxiella ELISPOT
Mononuclear cells were isolated from whole blood specimens (lithium heparin) drawn at 
regular phlebotomy, using Leucosep tubes (Greiner Bio-One Ltd # 163288) in combination 
with T-cell Xtend (TTK.610; Oxford Imunnotec Ltd, Abingdon, UK). As stimulating antigens, 
we used the commercially available lyophilized phase I and phase II antigens (#1227 
and #1123 respectively; Virion-Serion Immunodiagnostica GmbH, Wurzburg, Germany). 
Phytohaemagglutinin (PHA; Sigma L4144), anti-CD3 Mab (Mabtech, Sweden) and CEF-pool 
(CT370; U-Cy-Tech Biosciences, Utrecht, the Netherlands; a combination of CMV, EBV and 
influenza peptides) were used as stimulation controls. Negative control wells only contained 
mononuclear cells without stimulating antigens. Subsequently, 100 lL of mononuclear cells 
were seeded at a density of 250 000 cells per well in precoated wells of PVDF strip plates 
(ELISpotPRO; Mabtech) and incubated with 50 lL of antigens or controls during 16–20 h at 
37 °C and 5% CO2. The resulting number of spots corresponds with the number of individual 
T-cells producing IFN-γ after stimulation with C. burnetii antigens. After detection spots were 
enumerated using an ELISpot reader (Auto Immun Diagnostika GmbH, Strassberg, Germany). 
This work was a proof of principle study for the TRIQ (T-cell Response In Q fever) study 
approved by the local Ethical Committee (VCMO NL35867.100.11). All study subjects gave 
informed consent.
Study population
Study subjects were classified into three groups. Healthy control subjects (n = 9): 
negative serology (immunofluorescence assay: IFA, Focus Diagnostics or ELISA, Serion 
Immundiagnostica) for C. burnetii and no pre-existing comorbidities. Convalescent Q fever 
patients (n = 9): a documented history of Q fever with complete clinical recovery; no residual 
complaints or clinical signs of chronic Q fever, serological evidence of a past C. burnetii 
infection and no evidence of chronic disease (PCR negative and IFA phase I IgG < 1024 at 
≥6 months follow-up). Chronic Q fever patients (n = 3) fulfilled the diagnostic criteria of the 
Dutch consensus statement on chronic Q fever (Wegdam-Blans et al., 2011): a positive C. 
burnetii PCR in tissue and/or serum in the absence of acute Q fever infection (n = 2), or an IFA 
phase I IgG titre of ≥1024 and an endocarditis diagnosis using the Duke criteria or evidence of 
a vascular infection on PET/CT or ultrasound examination (n = 1).
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Main study endpoint
The spot count in the Coxiella ELISPOT for the three groups were assessed: healthy controls, 
convalescent patients and chronic Q fever patients. Assuming a Gaussian distribution, 
differences in mean spot counts between groups were assessed by one-way ANOVA.
Results
Coxiella burnetii-specific T-cell responses (mean ± SE) in convalescent Q fever patients were 
10 ± 5 spots to phase I antigen and 28 ± 13 spots to phase II antigen (Table 1). Using a cut-
off value of five spots for phase II reactivity, ELISPOT sensitivity for a past Q fever infection 
was 89%. Coxiella burnetii-specific T-cell responses in chronic Q fever patients were more 
pronounced: 194 ± 46 spots to phase I antigen and 219 ± 36 spots to phase II antigen. T-cell 
responses in chronic Q fever patients were significantly higher than those in convalescent 
patients: 18-fold for phase I antigen (P < 0.0001) and 8-fold for phase II antigen (P 0.0002). 
Table 1. Clinical characteristics and Coxiella ELISPOT results
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Table 1. Clinical characteristics and Coxiella ELISPOT results 
healthy controls convalescent Q fever chronic Q fever p value*
n=9 n=9 n=3
mean (±SD) age, range (years) 44,2 (10,8), 31-64 57,0 (15,5), 28-82 52,6 (15,3), 31-64
female / male 3 / 6 3 / 6 0 / 3
median months since diagnosis (range) n/a 8 (6-22) 1 (0-1)
phase I spots mean (±SD), range 0,8 (±1,0), 0-3 10 (±5), 1-42 194 (±46), 104-217 <0.01
phase II spots mean (±SD), range 0,2 (±0,4), 0-1 28 (±13), 1-120 219 (±36), 164-205 <0.01
PHA positive control spots mean (±SD), range 240 (±56), 58-350 272 (±25), 102-350 240 (±56), 172-350 0.87
CEF positive control spots mean (±SD), range 126 (±54), 16-211 101 (±62), 0-233 104 (±67), 18-236 0.95
negative control spots mean (±SD), range 0 0 0
* differences between means of all three groups, significance set at p<0.05
The proportion of phase II to phase I response was expressed as a ratio or stimulation index 
(SI = phase II spots/phase I spots). The SI value in convalescent patients was 2.8 compared to 
1.1 for chronic patients, indicating a tendency to shift to a phase I predominance in chronic 
disease. Stimulation controls in all patients and controls indicated adequate T-cell responses 
to the stimuli. Mean (± SE) T-cell responses in PHA-stimulated PBMCs (peripheral blood 
mononuclear cells) were adequate and not significantly different between all groups (P 0.87). 
Mean (± SE) T-cell responses in CEF-stimulated PBMCs did not significantly differ between 
all three groups (P 0.95). Responses in the healthy control group were negligible. We did not 
detect more than one spot after stimulation with either phase I or phase II antigens.
Discussion
In the Netherlands, a definitive chronic Q fever diagnosis currently is made on the basis 
of serology in combination with a positive serum PCR and in most cases, the presence of 
symptoms and a compatible clinical picture of endocarditis or vascular infection (Wegdam-
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Blans et al., 2011). In many Q fever patients, however, high levels of IgG phase I antibodies 
are found without a positive PCR and/or clinical symptoms (Delsing et al., 2010). The positive 
predictive value (PPV) of the previously widely advocated IFA phase I IgG titre of ≥800 for 
diagnosing chronic Q fever is 37%. Recent adjustment of this cut-off titre to ≥1600 only 
increased the PPV to 59% (Frankel et al., 2011). The sensitivity of PCR on a fresh serum sample 
in chronic Q fever is 64% (specificity 100%) (Fenollar et al., 2004). Therefore, a negative PCR 
in the presence of highly elevated antibody levels does not exclude chronic disease. For 
clinicians, there clearly is a need for a more reliable diagnostic test for chronic Q fever. 
In this exploratory study, the Coxiella ELISPOT adequately identified convalescent Q fever 
patients from healthy controls by demonstrating C. burnetii-specific T-cell IFN-γ production 
to both phase I and phase II antigens. Analogous to conventional serology, there was a 
clear phase II predominance. Specificity of the Coxiella ELISPOT for a past Q fever infection 
appears to be high, as T-cells from healthy controls did not react to both phase I and phase II 
C. burnetii antigens. False positive results because of cross-reactivity of the Coxiella ELISPOTs 
with other pathogens, however, remain a theoretical possibility. 
Chronic Q fever patients showed a distinct Coxiella ELISPOT profile. First, spot count for both 
phase I and phase II was much higher (18-fold for phase II, 8-fold higher for phase I) indicating 
a more vigorous immune response in vitro to both antigenic stimuli. This is analogous to 
conventional serology, classically showing both highly elevated IFA phase I and phase II IgG 
antibody levels (Delsing et al., 2010; Frankel et al., 2011). Second, Coxiella ELISPOT results 
from chronic Q fever patients were consistently shifted towards more phase I reactivity as 
evidenced by a significantly lower SI (phase II/phase I spots). This balanced phase I and 
phase II reactivity is not a consistent feature in the conventionally assayed IFA antibody titres 
(Delsing et al., 2010). 
There are some limitations to this pilot study. First, the limited number of patients does not 
allow for determination of a cut-off value for Coxiella ELISPOT results for diagnosing chronic 
Q fever. The consistent findings in phase I and phase II reactivity in chronic disease, however, 
are already statistically significant, but need confirmation in a larger cohort. Second, we used 
commercially available lyophilized C. burnetii antigens. These antigens are isolated from 
infected cells and can still contain tissue cell substrates, which could lead to false positive 
results. As we did not observe any reactivity for both antigens in healthy controls, such an 
aspecific reaction to these ‘impure’ antigens in the Coxiella ELISPOT is highly unlikely. Third, 
in contrast to the well-characterized conventional serological response to C. burnetii infection 
in time, the kinetic properties of the Coxiella ELISPOT assay are not yet known, precluding 
determination of cut-off values for diagnosing acute or chronic Q fever. 
Anticipating further research, we hypothesize that measuringa patient’s C. burnetii-specific 
T-cell responsiveness may better aid the clinician in accurately diagnosing a chronic from a 
non-chronic Q fever infection. In addition, such a test might prove a better tool for monitoring 
and guiding therapy than conventional serology. In the Netherlands, following the annual 
major Q fever outbreaks from 2007 to 2010, already more than 200 patients with a definite 
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or probable diagnosis of chronic Q fever have been identified (L.M. Kampschreur, pers. 
commun.). To validate the Coxiella ELISPOT for clinical use, a study comparing this assay 
to conventional serodiagnostics (serology and PCR) in a large cohort of Q fever patients is 
currently underway (the TRIQ study).
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Abstract
Diagnosis of ongoing or past infection with Coxiella burnetii, the causative agent of Q fever, relies heavily 
on serology: the measurement of C. burnetii-specific antibodies, reflecting the host’s humoral immune 
response. However, cell-mediated immune responses play an important, probably even more relevant, 
role in infections caused by the intracellular C. burnetii bacterium. Recent studies have investigated 
interferon-gamma (IFN-γ) based assays, including a whole-blood IFN-γ production assay and a Coxiella 
enzyme-linked immunospot (Coxiella ELISPOT), as potential diagnostic tools for Q fever diagnosis. Both 
are in-house developed assays using stimulating antigens of different origin. 
The main objective of this study was to compare the test performance of the IFN-γ production assay and 
the Coxiella ELISPOT for detecting a cellular immune response to C. burnetii in Q fever patients, and to 
assess the correlation between both assays. To that end, both tests were performed in a well-defined 
patient group of chronic Q fever patients (n = 16) and a group of healthy seronegative individuals (n = 17). 
Among patients, both the Coxiella ELISPOT and the IFN-γ production assay detected positive response 
in 14/16. Among controls, none were positive in the Coxiella ELISPOT, whereas the IFN-γ production 
assay detected positive results in 1/17 and 3/17, when using Henzerling and Nine Mile as stimulating 
antigens, respectively. 
These results suggest the Coxiella ELISPOT has a somewhat higher specificity than the IFN-γ production 
assay when Nine Mile is used as antigen stimulus. The assays showed moderate correlation: the 
Spearman correlation coefficient r ranged between 0.37–0.60, depending on the antigens used. Further 
investigation of the diagnostic potential for C. burnetii infection of both assays is warranted.
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Introduction
Q fever is a zoonotic disease that occurs worldwide and is caused by the gram-negative, 
intracellular bacterium Coxiella burnetii. The Netherlands experienced a major Q fever 
outbreak between 2007 and 2010, with over 4,000 reported human infections [1]. Acute Q 
fever mostly presents as a flu-like illness, pneumonia or hepatitis, but initial infections 
can be asymptomatic in more than 50% of cases [2]. Chronic Q fever is a rare but serious 
complication that occurs in approximately 5% of all patients following the acute infection. 
This persisting infection typically presents with endocarditis or vascular infection, and has 
significant mortality rates, especially in case of diagnostic and therapeutic delay [3]. 
Evaluating chronic C. burnetii infection is challenging. Measurement of serum antibodies 
against C. burnetii is currently the ‘gold standard’ for Q fever diagnosis [3]. Diagnosis of chronic 
Q fever relies heavily on detection of high IgG antibody titers against phase 1 C. burnetii. This 
serological criterion is combined with PCR for C. burnetii DNA on blood or tissue (if available) 
and clinical assessment of any nidus of chronic infection [4,5]. 
Both humoral and cell-mediated immune responses are involved in the host’s immunity 
against the intracellular C. burnetii bacterium [6–8]. Therefore, it makes sense to explore 
the value of complementing conventional serology with an assessment of host specific 
cell-mediated immune responses to detect a chronic infection with C. burnetii. To this end, 
new immunological blood tests have been developed that are based on cellular immunity, 
measuring T-cell derived interferon-c (IFN-γ) production in response to stimulation with 
C. burnetii. The first, the wholeblood IFN-γ production assay, was extensively investigated 
during a Q fever vaccination campaign and for the diagnosis of chronic Q fever [9–11]. The 
second, the Coxiella enzyme-linked immunospot (Coxiella ELISPOT), was explored in a small 
series of patients with past or chronic Q fever [12]. The IFN-γ production assay measures 
the amount of C. burnetii specific IFN-γ production,while the Coxiella ELISPOT measures the 
number of C. burnetii specific IFN-γ producing cells. These IFN-γ based assays are not yet 
routinely used for Q fever diagnosis. Both are in-house assays, using different stimulating 
antigens. The IFN-γ production assay uses in-house cultured Nine Mile phase 1 and the 
Q-vax vaccine containing Henzerling phase 1, while the Coxiella ELISPOT uses commercially 
available Nine Mile phase 1 and phase 2 antigens. 
In the aftermath of the Dutch Q fever outbreak, we had the opportunity to use both IFN-γ 
based tests in parallel in a group of well-defined chronic Q fever patients. Volunteers with no 
history of Q fever and with negative Q fever serology served as a control group. 
The purpose of this study was to compare the test performance (sensitivity and specificity) of 
the IFN-γ production assay and the Coxiella ELISPOT for detecting a cellular immune response 
to C. burnetii in Q fever patients and to determine the correlation between the assays.
Materials and Methods
Patients and control subjects
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Chronic Q fever patients (n = 16) were recruited from the outpatient clinics of the participating 
hospitals. All fulfilled the criteria for probable (n= 4) or proven (n= 12, of which 3 Q 
fevermendocarditis and 9 Q fever vascular infection) chronic Q fever according to the Dutch 
consensus statements on chronic Q fever [4]. Fourteen of the 16 patients were on long-term 
antibiotic treatment at inclusion. The median duration of antibiotic treatment at the time of 
blood collection was 21 months (range 0–59 months). The control individuals (n =17) were 
similar with respect gender, somewhat younger, but had no history of Q fever and had negative 
Q fever serology as measured by immunofluorescence assay (Focus Diagnostics, Cypress, CA, 
USA) (Table 1). Informed consent was obtained from all subjects before blood donation and the 
study was approved by the local ethics committee (CMO regio Arnhem-Nijmegen).
Table 1. Characteristics of chronic Q fever patients and control individuals.
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IFN-γ production assay  
The IFN-γ production assay was performed as previously described [9]. In short, heparinized 
whole blood was aliquoted into four separate 1.5 mL tubes at 0.5 mL per tube. The tubes 
were inoculated with either 10 mg/mL PHA (Sigma, St. Louis, MO), 100 ng/ml Q vax vaccine 
(see below), 10‘7/mL heatinactivated C. burnetii Nine Mile phase I (see below), or nothing. 
The tubes were incubated in-vitro for 24 hours at 37uC and 5% CO2. The IFN-γ production 
was measured in the supernatant by ELISA (Pelikine compact, Sanquin, Amsterdam). Net 
IFN response was expressed as the concentration of IFN-γ in the stimulated sample minus 
that in the unstimulated sample. The Q-vax vaccine (CSL Biotherapies, Vic., Australia), 
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The IFN-γ production assay was performed as previously described [9]. In short, heparinized 
whole blood was aliquoted into four separate 1.5 mL tubes at 0.5 mL per tube. The tubes were 
inoculated with either 10 mg/mL PHA (Sigma, St. Louis, MO), 100 ng/ml Q vax vaccine (see below), 
10‘7/mL he tinactivat d C. burnetii Nine Mile phase I (see below), or nothing. The tubes wer  
incu ated in-vitro for 24 hours at 37uC and 5% CO2. The IFN-γ production was measured in the 
supernatant by ELISA (Pelikine compact, Sanquin, Amsterdam). Net IFN response was expressed 
as the concentration of IFN-γ in the stimulated sample minus that in the unstimulated sample. 
The Q-vax vaccine (CSL Biotherapies, Vic., Australia), contains formalin-inactivated whole cell 
phase 1 Henzerling strain. Heat-inactivated phase 1 C. burnetii Nine Mile (NMI, RSA493) was kindly 
provided by H.I. Roest (Central Veterinary Institute, Lelystad, the Netherlands). Details about 
culture and preparation of this stimulating antigen are described elsewhere [9].
Coxiella ELISPOT
The Coxiella ELISPOT was performed on peripheral blood mononuclear cells (PBMCs) 
isolated from heparinized blood and stimulated for 16–20 hours, as described before [12]. 
In precoated wells of PVDF strip plates (ELISpotpro; Mabtech) 100 mL of mononuclear cells 
were seeded at a density of 250,000 cells per well, and incubated with 50 mL of antigens, 
PHA (2.5 mg/mL) or nothing. As stimulating antigens, commercially available formalin-
inactivated phase 1 and phase 2 Nine Mile (NMI and NMII, Virion-Serion Immunodiagnostica 
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GmbH, Wu¨rzburg, Germany) were used. After incubation, the resulting number of spots, 
representing the number of individual T-cells producing IFN-γ following stimulation with 
C. burnetii antigens, were detected and enumerated using an ELISpot reader (Auto Immun 
Diagnostika GmbH, Strassberg, Germany).
Statistics
Statistical analysis was performed using GraphPad Prism 5. Median (6 interquartile range) 
IFN-γ production and number of spots were compared between groups using Mann-Whitney 
Utests. Receiver Operating Characteristics (ROC) curves analysis were used to derive a cutoff 
for positivity of either assay. The cutoff was determined from the ROC curve by choosing the 
value that yielded empirical optimal sensitivity and specificity. Correlation was reported by 
calculating the Spearman’s r with 95% Confidence Interval.
Results and Discussion
The amount of IFN-γ as measured in the IFN-γ production assay and the spot count obtained 
in the Coxiella ELISPOT were evaluated. The individual values are shown in Figure 1 for patients 
and control subjects separately. The median IFN-γ response to the Henzerling antigen in the 
patients was 440 pg/mL (IQR 62–612 pg/mL), whereas in control subjects, this was 0 pg/mL 
(IQR 0–0 pg/mL). The median IFN-c response to the NMI antigen in the patients was 3238 pg/
mL (IQR 534–6564 pg/mL), whereas in control subjects, this was 126 pg/mL (IQR 14–250 pg/
mL). The median ELISPOT spot count after NMI stimulation was 44 (IQR 15–94) in patients 
and 0 (IQR 0–0) in controls, and after NMII stimulation 71 (IQR 23–100) in patients and 0 (IQR 
0–0) in controls. In both assays, the differences between patients and control subjects were 
significant for each stimulating antigen. All of the samples tested responded to PHA mitogen. 
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Figure 1. Results of the IFN-γ production assay and Coxiella ELISPOT in chronic Q fever patients and control 
subjects. In vitro IFN production by whole blood in response to Henzerling and Nine Mile phase 1 antigens was 
measured in the IFN-γ production assay. The number of IFN-γ positive cells in response to Nine Mile phase 1 and 
Nine Mile phase 2 antigens was measured in the Coxiella ELISPOT. Individual values of patients and controls are 
shown separately, and the lines indicate the medians. Patients and controls were compared using the Mann-
Whitney U-test. ***P,0.001, **P,0.01. Abbreviations: NMI, Nine Mile phase 1; NMII, Nine Mile phase 2; IFN-c, 
interferon-gamma. 
 
and control subjects were significant for each stimulating antigen. All of the samples tested 
responded to PHA mitogen.  
To establish a cutoff for a positive response in both assays for each of the antigens, ROC 
curves were constructed (Figure 2). Cutoffs were derived from ROC curve analysis to yield 
empirical optimal sensitivity and specificity. For the IFN-γ production assay this resulted in a 
cutoff of 45 pg/mL or 365 pg/mL when using the Henzerling or the NMI as stimulating 
antigen respectively. For the Coxiella ELISPOT, this resulted in a cutoff of 5 spots to both 
NMI and NMII. Given these cutoffs, the IFN-γ production assay detected positive response in 
14/16 and the Coxiella ELISPOT was positive in 14/16 among the patients. Among the 
controls, the IFN-γ production assay detected positive response in 1/17 and 3/17, when 
using Henzerling and Nine Mile as stimulating antigens respectively, whereas none were 
positive in the Coxiella ELISPOT.  
These results suggest that the assays have comparable sensitivity in this population, but the 
Coxiella ELISPOT has a higher specificity than the IFN-c production assay with Nine Mile as 
an antigen stimulus. This might be due to different antigens being exposed after heat-
Figure 1. Results of the IFN-γ production assay and Coxiella ELISPOT in chronic Q fever patients and control sub-
jects. In vitro IFN production by whole blood in response to Henzerling and Nine Mile phase 1 antigens was measu-
red in the IFN-γ production assay. The number of IFN-γ positive cells in response to Nine Mile phase 1 and Nine Mile 
phase 2 antigens was measured in the Coxiella ELISPOT. Individual values of patients and controls are shown sepa-
rately, and the lines indicate the medians. Patients and controls were compared using the Mann-Whitney U-test. 
***P,0.001, **P,0.01. Abbreviatio s: NMI, Nine Mile phase 1; NMII, Nine Mile phase 2; IFN-c, interferon-gamm .
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To establish a cutoff for a positive response in both assays for each of the antigens, ROC 
curves were constructed (Figure 2). Cutoffs were derived from ROC curve analysis to yield 
empirical optimal sensitivity and specificity. For the IFN-γ production assay this resulted in a 
cutoff of 45 pg/mL or 365 pg/mL when using the Henzerling or the NMI as stimulating antigen 
respectively. For the Coxiella ELISPOT, this resulted in a cutoff of 5 spots to both NMI and NMII. 
Given these cutoffs, the IFN-γ production assay detected positive response in 14/16 and the 
Coxiella ELISPOT was positive in 14/16 among the patients. Among the controls, the IFN-γ 
production assay detected positive response in 1/17 and 3/17, when using Henzerling and 
Nine Mile as stimulating antigens respectively, whereas none were positive in the Coxiella 
ELISPOT. 
These results suggest that the assays have comparable sensitivity in this population, but the 
Coxiella ELISPOT has a higher specificity than the IFN-c production assay with Nine Mile as an 
antigen stimulus. This might be due to different antigens being exposed after heat-inactivation 
of the NMI strain as compared to the antigens present on the formalin-inactivated bacteria. 
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Figure 2. ROC curves of the IFN-γ production assay and the Coxiella ELISPOT. ROC curves are shown for each 
assay with each stimulating antigen separately. Abbreviations: NMI, Nine Mile phase 1; NMII, Nine Mile phase 2; 
IFN-γ, interferon-gamma. 
 
Furthermore, it is very well possible that the IFN-γ production assay and the Coxiella 
ELISPOT assay do not measure the same features of the immune response. Although both 
tests measure Coxiella specific IFN-γ production, the Coxiella ELISPOT assay singles out 
and quantifies the T lymphocyte compartment, whereas whole blood stimulation also 
includes blood IFN-γ producing NK cells, reflecting also the innate part of the immune 
response. However, true positives in the control group cannot be excluded which in turn 
may underestimate specificity. A seroprevalence study in the Q fever epidemic area among 
patients with a valvular risk factor for chronic Q fever found 20.4% of the people to be 
seropositive for C. burnetii [13]. As the control subjects lived close to or in the epidemic area, 
although not having a Q fever history or detectable anti-C. burnetii antibodies, it is not 
unthinkable that any of the control subject could have a past exposure to C. burnetii that 
was not picked up by serology. Of note, two of the three control subjects that produced 
substantial amounts of IFN-γ after NMI antigen	 stimulation, also showed minimal response 
below the cutoff in the Coxiella ELISPOT.  
In the patient samples, we determined the correlation between the amount of IFN-γ 
produced in the IFN-γ production assay and the number of IFN-γ-producing cells in the 
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underestimate specificity. A seroprevalence study in the Q fever epidemic area among patients 
with a valvular risk factor for chronic Q fever found 20.4% of the people to be seropositive for C. 
burnetii [13]. As the control subjects lived close to or in the epidemic area, although not having 
a Q fever history or detectable anti-C. burnetii antibodies, it is not unthinkable that any of the 
control subject could have a past exposure to C. burnetii that was not picked up by serology. Of 
note, two of the three control subjects that produced substantial amounts of IFN-γ after NMI 
antigen stimulation, also showed minimal response below the cutoff in the Coxiella ELISPOT. 
In the patient samples, we determined the correlation between the amount of IFN-γ produced 
in the IFN-γ production assay and the number of IFN-γ-producing cells in the Coxiella ELISPOT 
(Figure 3). The correlation between the values obtained in the two assays, each employing two 
stimulating antigens, was determined separately, resulting in a total of four comparisons. 
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Figure 3. Correlation between the amount of C. burnetii-specific IFN-γ production and the number of IFN-γ positive 
cells. The individual values of chronic Q fever patients (n = 16) were used to determine the correlation between the 
IFN-γ production as measured with the IFN-γ production assay, and the number of IFN-γ positive cells as measured 
with the Coxiella ELISPOT. Each graph shows the correlation between the resulting values of the two assays, with 
either one of the stimulating antigens. On the Y-axes, the IFN-γ production is shown after stimulation with NMI 
(upper graphs) and Henzerling antigens (lower graphs). On the X-axes, the spot count is shown after stimulation 
with NMI (left graphs) and NMII (right graphs) antigens. The Spearman’s correlation coefficient r (95% Confidence 
Interval) is given for each comparison. Abbreviations: NMI, Nine Mile phase 1; NMII, Nine Mile phase 2; IFN-γ, 
interferon-gamma. 
 
indicating a moderate to strong correlation. The discrepancies between both types of assays 
can be explained by the different origins and concentrations of stimulating antigens, the 
different phase variation, or, as mentioned previously, the method of inactivation of the 
antigen stimuli. Moreover, it may well be true that the amount of IFN-γ released is not 
directly related to the number of IFN-γ positive cells. IFN-γ based assays are used for 
detection of immunity to Mycobacterium tuberculosis and commercial kits are available for 
the two types of assays, e.g. the QuantiFERON-TB and the T Spot TB [14]. These assays 
Figure 3. Correlation between the amount of C. burnetii-specific IFN-γ production and the number of IFN-γ 
positive cells. The individual values of chronic Q fever patients (n = 16) were used to determine the correlation 
between the IFN-γ production as measured with the IFN-γ production assay, and the number of IFN-γ positive 
cells as measured with the Coxiella ELISPOT. Each graph shows the correlation between the resulting values of 
the two assays, with ither one of the stimulating antigens. On the Y-ax s, he IFN-γ production is shown after 
stimulation with NMI (upper graphs) and Henzerling antigens (lower graphs). On the X-axes, the spot count is 
shown after stimulation with NMI (left graphs) and NMII (right graphs) antigens. The Spearman’s correlation 
co fficient r (95% Confiden e Interval) is given for each comparison. Abbr viations: NMI, Nine Mile phase 1; 
NMII, Nine Mile phase 2; IFN-γ, interferon-gamma.
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The Spearman correlation coefficient r ranged between 0.37–0.60, indicating a moderate to 
strong correlation. The discrepancies between both types of assays can be explained by the 
different origins and concentrations of stimulating antigens, the different phase variation, 
or, as mentioned previously, the method of inactivation of the antigen stimuli. Moreover, it 
may well be true that the amount of IFN-γ released is not directly related to the number of 
IFN-γ positive cells. IFN-γ based assays are used for detection of immunity to Mycobacterium 
tuberculosis and commercial kits are available for the two types of assays, e.g. the 
QuantiFERON-TB and the T Spot TB [14]. These assays have been reported to be at least as 
accurate as the tuberculin skin test to detect exposure to M. tuberculosis. The correlation 
between the two types of IFN-γ based assays for tuberculosis as previously reported in the 
literature, are better (r= 0.69 and r =0.80) than what we observed evaluating these diagnostic 
platforms in C. burnetii infection [15,16].
In conclusion, the two IFN-γ based assays had a similarly high  sensitivity for detecting C. 
burnetii infection and the correlation between both test was moderate. The IFN-γ production 
assay in whole blood has the practical advantage of relative technical simplicity over the 
more laboriously intensive Coxiella ELISPOT. The Coxiella ELISPOT, however, seemed to 
be more specific with Nine Mile as an antigen stimulus. These observations, and previous 
studies of these IFN-γ based assays in C. burnetii infection, show the potential of measuring 
cell-mediated immune response in Q fever and warrant further investigation of these assays 
in larger cohorts of Q fever patients.
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General discussion 
The first Dutch human Q fever outbreak presented clinicians with many challenges regarding 
diagnosis and management of the disease. At the same time, it provided ample opportunity 
for researchers to observe, explore and investigate this complex disease from the vantage 
point of various scientific research disciplines, including the fields of epidemiology, 
microbiology, clinical medicine and immunology. This thesis contains several clinical studies 
performed mainly in patients from the early stages of the outbreak, exploring various aspects 
of Q fever and its longterm clinical outcomes.
Emergence of C. burnetii as a novel causative agent of pneumonia
In the epicenter of what would be the start of the largest documented Q fever outbreak 
ever reported, our data indeed support the hypothesis that C. burnetii emerged as a novel 
aetiological agent of pneumonia in May 2007. The aspecific nature of Q fever symptoms, its 
generally mild clinical course and perhaps sheer infamiliarity of attending physicians with 
the disease at the outset of the outbreak could have led to an underreporting of Q fever 
cases in 2007 and the preceding years. Interestingly in this regard, Van den Wijngaard et 
al. found retrospective statistical evidence of clustering of hospitalizations of possible and 
plausible Q fever pneumonia cases starting as early as 2005. Lack of possibility of serological 
testing, however, precluded definite confirmation of these outbreak clusters as being a Q 
fever outbreak [1]. Schimmer et al. Found a low sero-prevalence of 2,4% in the Netherlands 
in the period leading up to the outbreak [2]. In 2014 a sero-epidemiological study performed 
in Herpen included 70% of its total adult population and found a staggering 33,8% 
seroprevalence for C. burnetii antibodies, further underlining the massive impact and scope 
of Q fever in the epidemic region since its emergence in the spring of 2007 [3].
Clinical presentation, serological and echocardiographic findings of Q fever patients 
from the initial stages of the outbreak: implications for clinical practice
The finding of an aspecific, flu-like syndrome with or without atypical respiratory tract 
infection as the main clinical Q fever manifestation in the first cohort of patients tallies with 
earlier research [4,5]. There was a striking level of incapacitating and protracted fatigue in 
our Q fever patients in 52% at 6 months and 26% at 1 year following primary infection. Other 
research groups have reported similar findings in combination with a marked reduced quality 
of life [6-9]. The finding of prolonged symptomatology will be discussed in the following 
paragraph of this chapter.
Using a commercially available IFA we observed a typical serological response to Coxiella 
burnetii infection with strikingly high levels of antibodies to both phase I and phase II 
antibodies. This serological response was characterized by an increase in antibody titers up 
to 3 months and a subsequent decrease in the following 9 months. The phase I IgG antibody 
kinetic, with a titer peak at 3 months, is different from available literature on IFA serological 
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patterns in the follow-up of acute Q fever, that shows a rather slow and gradual increase of 
phase I IgG antibodies [10,11]. None of our patients developed a clinical picture compatible 
with chronic Q fever and all patients showed a spontaneous subsequent decline in antibody 
titres. This finding has considerable clinical importance as the appearance of high antibody 
levels, especially phase I IgG, can wrongly be taken as supposed proof of chronic disease. 
To aid in the diagnosis and management of chronic Q fever, a new guideline was proposed 
by the Dutch Q fever consensus group in 2012, stressing the importance of the fact that 
chronic C. burnetii infection is first and foremost a clinical diagnosis, its definite diagnosis 
requiring integration of data on C. burnetii antibody titres and PCR, imaging techniques and 
the presence of predisposing risk factors in the host [12].  
An active search for cardiac valvular abnormalities and serological surveillance following 
acute Q fever have been advocated to identify chronic Q fever in an early stage and to trigger 
prolonged prophylactic antibiotic treatment in case of even minor cardiac valvulopathy [13-
15]. Q fever endocarditis is reported to develop in up to 39% of patient with known pre-existing 
cardiac valvulopathy [16]. Interestingly, minor, clinically insignificant valvular disease (trace 
and mild defects) has a high prevalence in any unselected population [17]. For example, the 
prevalence of ‘trace’ mitral valve regurgitation is 40% and can therefore be considered to 
be a physiological phenomenon without clinical importance. The prevalence of mitral valve 
prolaps and bicuspid aortic valve is estimated at 2-3% and circa 1% respectively [18,19]. 
During follow-up of the outbreak cluster in Herpen, echocardiography was performed in 
most Q fever patients, confirming a high prevalence of minor cardiac valvulopathies, but 
none of the patients developed chronic disease. By contrast with existing publications, our 
data indicate a low risk of progression to Q fever endocarditis. 
This contrasting result may be explained by several factors including selection bias,  lack of 
specification of valvular defect severity in published retrospective research, strain differences 
of C. burnetii and differences in host characteristics. In addition, these studies were carried 
out in the setting of a large Q fever epidemic, as opposed to most studies on chronic Q 
fever incorporating and collecting Q fever patients from endemic regions over prolonged 
periods of time [13,14,16,20]. In these studies, the risk of endocarditis in patients with acute 
Q fever and pre-existing cardiac valve defects was estimated to be up to 39%, but many 
of the patients had prosthetic valves [16]. In their landmark study on Q fever endocarditis, 
Million and colleagues describe a highly selective cohort with valve defects mostly caused 
by rheumatic fever (30%, about half of all specified valvular disease), a disorder that is rare 
in most developed countries [20]. Furthermore, 30% of their patients had infected prosthetic 
valves. Degenerative valvular disease was present in only 5%,1 whereas this type of valvular 
defect is highly prevalent in the general population (22% in our study) [17]. 
The limited number of patients in our studies do not allow to determine the relative 
risk of developing chronic Q fever for patients with mild or even clinically significant 
degenerative valvulopathy, but it’s clear that the absolute risk, at least in the case of a 
minor valve insufficiency, is likely to be small enough to withhold prolonged profylactical 
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antibiotic treatment and perform only serological follow-up. The a priori chance of finding 
a relevant but clinically silent cardiac valve abnormality by general cardiac screening is low. 
Furthermore, the previously estimated 39% chance of developing chronic Q fever is very likely 
not applicable for all valvulopathies and probably lower than has previously been estimated 
in case of minor valvulopathies. Interestingly in this regard, in 2012, Kampschreur et al. found 
a prevalence of 7,8% of probable and proven chronic Q fever cases in a group of patients 
in the Netherlands with a history of cardiac valve surgery and seropositivity for C. burnetii 
antibodies [21]. In addition, a recent study by Kampschreur et al. identified and quantified 
risk factors for development of chronic Q fever after C. burnetii infection. Using a case-control 
design, several major independant risk factors for development of chronic disease were 
identified: increasing age, previous valvular surgery, aneurysms and renal insufficiency. Of 
note and in contrast with previous studies on this subject, no association was found between 
(mild) non-surgical heart valve pathology and chronic Q fever [22]. 
In response to the findings of these and other studies in the Netherlands, the French research 
group of professor Raoult, from the worldwide centre of expertise on Q fever in Marseille, 
published data of the French database of Q fever patients stating a high relative risk of 
patients with chronic Q fever to have a bicuspid aortic valve, a mitral valve prolapse or a 
moderate mitral or aortic valve insufficiency [23]. In this letter to the editor, there was no 
mention of minor valvulopathies (trace and mild defects) being significantly associated 
with chronic Q fever. In addition, it remains unclear whether the described valvulpathies 
were clinically silent and whether the congenital valve abnormalities (bicuspid aortic valve 
or mitral valve prolapse) were uncomplicated or complicated by an accompanying valvular 
insufficiency and/or stenosis. 
In 2014, the same research group reported the results of a follow-up prospective study of 
acute Q fever patients with significant valvulopathy (n=31) stating an invariable (13/13) 
progression rate to Q fever endocarditis in patients without or incomplete antibiotic 
prophylaxis [24]. Conversely, patients with significant cardiac valvulopathy who received 
antibiotic prophylaxis invariably (18/18)  did not developed chronic disease. Again there are 
several concerns regarding the applicability of these data in clinical practice; data are from 
a highly selective cohort of patients analysed and treated in a worldwide reference centre, 
patients had a very high prevalence of significant cardiac valvulopathy (43%), and diagnosis 
of chronic disease was made mostly on marginally increased serological titres within an 
unusually short time frame after acute Q fever, suggesting the possibility of an inadvertent 
misdiagnosis of chronic Q fever in at least some of the cases [25]. 
In the years after the first outbreak, additional follow-up studies from the Netherlands have 
been published, including larger patient numbers, providing further insight into the longterm 
outcome of acute C. burnetii infection and risk factors associated with the development of 
chronic Q fever. Van der Hoek et al. identified 11 chronic Q fever cases in a group of 686 Q 
fever patients with a 12 month serological follow up period [26]. Complete clinical data were 
available from 9 of these 11 chronic Q fever patients, 3 of whom developed endocarditis. All 
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these 3 patients had known pre-existing cardiac valve disease and no cases of endocarditis 
due to clinically silent cardiac valvulopathy were encountered. In 2014, the entire adult 
population (n=2161) of the town of Herpen was offered serological screening for Q fever [27]. 
Of the 1517 participants (70,3%), 33,8% were seropositive and 3 patients had developed 
clinically diagnosed chronic Q fever, all of whom had known risk factors (1 patient with an 
aortic aneurysm and stent, 1 patient with a history of cardiac valve surgery and 1 patient with 
impaired renal function). No unexpected Q fever endocarditis cases were detected, 7 years 
after the first outbreak [27].
Identifying patients at risk of developing chronic Q fever is very important, as early detection 
and treatment of chronic disease is associated with better survival [15,24]. The association 
of chronic Q fever with (minor) non-cardiac surgery cardiac valve defects is likely to be 
smaller than has previously been estimated and calls into question the use of screening 
echocardiography for every Q fever patient. The harm of low-threshold administration 
of long-term antibiotic prophylaxis in case of minor valvulopathies might outweigh the 
possible benefit. Clearly, prophylactic antibiotic treatment after acute Q fever episode has 
the potential to prevent evolution to chronic disease of high-risk patients, but exactly which 
patients are most likely to benefit from such a strategy remains to be determined [25]. In the 
Netherlands, invariably performing a screening echocardiography for every Q fever patient 
was abandoned in favor of a pragmatic approach, employing serological follow-up for all Q 
fever patients and targeted screening of known risk groups [28,29].
Long term health status of Q fever patients  
One year after primary infection, Q fever patients from the 2007 Herpen outbreak had a 
significantly lower health status in many subdomains of the main domains ‘symptoms’ and 
‘functional impairment’, when compared to age-, sex- and geographically matched controls. 
Overall QoL and health-related QoL were significantly decreased in both patients and 
controls. This impairment in health status persisted in the same group of patients from the 
first outbreak at 4 years follow-up. This persistence of impairment in many sub-domains of 
health status after 4 years in the majority of affected Q fever patients is marked, and suggests 
an absence of dynamics in symptomatology after 1 year. Research groups in England, 
Australia and Canada have similarly found consistent and clearly decreased very long-term 
health status outcomes in Q fever patients, using various questionnaires and study designs 
[6-9].
Remarkably, health status scores of controls without a clinical history of Q fever but 
with serological evidence of exposure to C. burnetii were not statistically different from 
seronegative controls, suggesting that clinical expression of acute Q fever infection is an 
essential factor in the subsequent sustained decrease in health status. Severity of initial illness 
previously indeed has been shown to be the best predictor of subsequent development of 
a post-infective fatigue syndrome in both viral and non-viral pathogens, including Q fever 
[30]. Moreover, the same genetic polymorphisms in cytokine genes with critical roles in the 
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inflammatory reponse to infection, underpin both the severity of the acute sickness and the 
average time to recovery across varied infections, including Q fever [31-34].
Our findings lend support to the notion of an extremely protracted reconvalescence phase 
and decreased sustained health status after primary infection in a significant proportion of 
Q fever patients. 
Additional studies assessing longterm health status in Q fever patients in the Netherlands 
found similar results. Morroy et al. found similar levels of fatigue and decreased health status 
in 515 Q fever patients with a follow-up period of 12-26 months [9]. Interestingly in this study, 
health status score did not differ significantly at 12 months vs. 17-26 months follow-up, 
suggesting an absence of dynamics in health status after 1 year. Van Loenhout et al. studied 
a group of 336 Q fever patients and found a reduced health status at 24 months in more than 
one out of three patients [35].
The acknowledgement and acceptance of a protracted fatigued state following acute Q 
fever in about 20% of patients, sometimes designated post-Q fever fatigue syndrome (QFS); 
however, is not universal [36,37]. A QFS diagnosis relies solely on the patient’s own account 
of symptoms. In clinical practice, QFS patients remain indistinguishable from patients with a 
complete recovery after primary infection with C. burnetii, as they do not meet the criteria for 
chronic Q fever infection [38,39]. 
The main reasons for this reluctance seem to be the incompletely understood pathophysiology 
of QFS, the absence of a diagnostic test and possibly, fear of patients’ financial compensation 
claims. Moreover, post-infectious protracted fatigue states following other bacterial and viral 
pathogens such as Bartonella, Legionella, Epstein–Barr virus, cytomegalovirus and West Nile 
virus, suggest a non pathogen-specific pathogenesis of postinfectious fatigue syndromes 
[30,40]. 
Interestingly in this regard, a recent Dutch study, using the NCSI and the Short Form 36 (SF-
36), compared the health status of 309 Q fever patients and 190 patients with Legionnaires’ 
disease and found severe impairment of various health status sub-domains including 
fatigue for both diseases 1 year after onset of illness [41]. Another smaller study from The 
Netherlands compared 50 patients with a lower respiratory tract infection (LRTI) caused by 
Q fever with 32 non-Q fever LRTI patients with a follow-up period of 10–19 months. With the 
exception of the sub-domain ‘subjective pulmonary symptoms’, no difference was observed 
in health status for all other measured subdomains using the NCSI [42]. Interestingly, as in 
our study, significant proportions of Q fever patients experienced severe fatigue (40%) and 
severely impaired general quality of life (40%). 
Recently, an elegant new paradigm of persistence of Coxiella antigenic non-viable cell 
residues after primary infection in interaction with immunogenetic polymorphisms in the 
host has been put forward to better explain the chronic sequelae of acute Q fever, including 
QFS [38].
There are numerous studies probing the underlying pathophysiology of QFS that show 
significant differences between Q fever patients with and without QFS with regard to 
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gene expression [32,33,43], serum cytokine levels [34] and peripheral blood mononuclear 
cells cytokine release patterns after stimulation with C. burnetii antigens [31,34]. There 
are, however, several shortcomings that impede a thorough interpretation and unifying 
concept of QFS pathophysioloy; a lack of a clear definition of QFS, small patient numbers 
and different laboratory techniques and protocols that do not allow for comparison and 
validation of obtained results. Moreover, there is no validated evidence-based treatment for 
QFS. To address this issue, a large randomized placebo-controlled prospective clinical trial is 
underway in The Netherlands, assessing the efficacy of longterm treatment with doxycycline 
and cognitive behavioural therapy in patients with QFS [44].
Developing a new diagnostic tool for Q fever: measuring the host’s C. burnetii specific 
interferon gamma production 
In routine clinical practice, diagnosis of acute Q fever can readily be established with a 
high degree of sensitivity and specificity by demonstrating the patient’s C. burnetii specific 
antibody response [4,5]. Contrastingly, serology has a rather poor diagnostic performance 
in identifying chronic Q fever and has no known diagnostic potential in diagnosing QFS 
[38,39]. Clearly, there is a need for a better test that can adequately identify or even predict 
patients who (will) develop an adverse clinical outcome after acute Q fever. We hypothesized 
measuring a patient’s cellular immunity might better identify different clinical outcomes after 
C. burnetii infection. Analogous to IFN gamma release assays for tuberculosis, we devised a 
new platform using the ELISPOT technique, specifically modified to measure the patient’s 
T-cell IFN gamma release to stimulation with C. burnetii specific antigens: the Coxiella 
ELISPOT (see Chapter 7).
The Coxiella ELISPOT adequately identifies convalescent Q fever patients from healthy 
controls by demonstrating C. burnetii-specific T-cell IFN-c production to both phase I and 
phase II antigens. Specificity of the Coxiella ELISPOT for a past Q fever infection appears to 
be high. We showed that measuring the host’s T-cell C. burnetii specific interferon gamma 
production is feasible and different clinical outcomes (past non-chronic Q fever infection 
and chronic C. burnetii infection) after acute Q fever were associated with different Coxiella 
ELISPOT profiles. Comparison of our Coxiella ELISPOT with a IFN-gamma production assay 
devised by the research group from Nijmegen (Schoffelen et al.) showed a similarly high 
sensitivity for detecting C. burnetii infection with a moderate correlation between both tests 
(see Chapter 8). These observations, and previous studies of these IFN-gamma based assays 
in C. burnetii infection, show the potential of measuring cell-mediated immuneresponse in 
Q fever. 
Since these first reports, the value of a C. burnetii IGRA (the IFN-gamma production assay) 
has been demonstrated in diagnosing past (non-chronic) Q fever [45], measuring C. burnetii 
vaccination response [46], and combined with measurement of IL-2 release, identifying 
QFS patients [47], chronic Q fever patients [48] and monitoring therapeutic succes in the 
treatment of chronic Q fever [49].
General discussion and perspectives for future research
Ch
ap
te
r 9
103
Perspectives for future research
Infection with the C. burnetii bacterium can take on many clinical guises, if any, and produces 
an adverse long term clinical outcome in a significant proportion of affected patients. Acute 
symptomatic infection, recognised in the appropriate epidemiological setting, is readily 
diagnosed using conventional serology and effectively treated with doxycycline. In stark 
contrast, diagnosis and treatment of the long term adverse outcomes of C. burnetii infection; 
chronic disease and QFS, are often very arduous and require a highly individualised patient-
tailored approach. 
In the case of chronic Q fever, there is a need for further clarification which risk factors, both 
those present in the host and the pathogen, contribute to the development of a chronic form 
of C. burnetii infection. For every clinically manifest case of Q fever during the successive Q 
fever outbreaks in the Netherlands, an estimated 12,6 cases occurred subclinically, making 
this patient group a large reservoir at risk for development of chronic disease [50]. Expanding 
research to identify risk factors for development of chronic Q fever in this population can aid 
in early detection, treatment and possibly even prevention of chronic disease. 
In the case of QFS, as this long term adverse outcome by far constitutes the largest portion of 
the total disease burden, further elucidation of the pathofysiological mechanisms is urgently 
needed. In addition, a clear and internationally accepted uniform definition of this syndrome 
and follow-up parameters, will aid in comparising obtained research results between research 
groups and help devise new study protocols in search for an effective treatment strategem. 
The current shortcomings in conventional diagnostic and monitoring tools in chronic Q 
fever and QFS, highlight the largely incomplete understanding of the pathophysiology of C. 
burnetii infection. The promising results of diagnostic tools that include measurement of the 
cellular immune respons emphasize the pivotal role of host-pathogen interaction in Q fever. 
Measuring the host’s immune response to better identify and follow-up chronic disease and 
possibly even QFS is feasible and deserves to be explored. 
Anticipating further research, we hypothesize that a test measuring a patient’s C. burnetii-
specific cellular responsiveness may better aid the clinician in accurately diagnosing C. 
burnetii infection in all its manifestations, especially in the setting of chronic Q fever and 
QFS. In addition, such a test might prove a better tool for monitoring and guiding therapeutic 
interventions. 
Conclusions
This thesis contains several exploratory studies on Q fever in humans, with an emphasis on 
clinical observations, long-term quality of life following infection and the development of a 
new diagnostic Q fever assay. 
The data in this thesis support the hypothesis that Coxiella burnetii emerged as a novel 
causative agent of pneumonia in the Netherlands in May 2007. 
The first systematic observations on clinical presentation, serology and echocardiographic 
findings in Q fever patients from the initial stages of the outbreak in the Netherlands are 
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presented. Q fever mainly presented as a mild febrile flulike illness. Overall prevalence of mild 
cardiac valvulopathy was high, but the incidence of chronic Q fever in case of mild, clinically 
insignificant valvulopathy was lower than has previously been estimated. This calls into 
question the use of screening echocardiography and application of long-term profylactic 
antibiotic treatment for these mild cardiac valve defects. 
A significant proportion of Q fever patients exhibit high levels of undue fatigue and a sustained 
decrease in many aspects of health status at 1 and 4 year follow-up.  
Detecting C. burnetii specific interferon gamma production for diagnosing Q fever by 
the Coxiella ELISPOT is feasible and shows promise in terms of diagnostic performance. 
Comparison of the Coxiella ELISPOT with the Whole Blood Interferon Gamma production 
Assay showed moderate correlation. Further investigation of the diagnostic potential for C. 
burnetii infection of both assays is warranted.
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Summary
The first Dutch human Q fever cases in the spring of 2007 heralded a massive outbreak 
that would progressively unfold itself in annual seasonal incidence waves until 2011. The 
emergence of C. burnetii as a human pathogen on this unprecedented and unforeseen scale 
was linked to Q fever abortion waves on dairy goats and sheep farms in the epidemic region 
starting as early as 2005. As of 2011, the human Q fever disease burden amounted to more 
than 4000 notified acute Q fever cases and an additional estimated 44000 unnotified cases, 
as can be inferred from sero-epidemiological surveys. 
At the outset of the epidemic, evidence-based validated protocols regarding diagnosis 
and follow-up of acute Q fever were lacking in the Netherlands. Available literature on 
diagnosis and follow-up of acute and chronic Q fever had almost exclusively been generated 
by a dedicated research group from a single reference centre of expertise from France. It 
remained unclear whether these research findings could be extrapolated and whether 
recommendations regarding clincial diagnosis and follow-up could be applied to the same 
effect in the setting of the unfolding massive Dutch Q fever outbreak. On the one hand, this 
posed a major challenge for clinicians and other health care workers in managing acute 
disease and preventing long-term Q fever sequelae in the early stages of the epidemic. On 
the other hand, the Q fever outbreak provided ample opportunity for researchers to observe, 
explore and investigate this complex disease from the vantage point of various scientific 
research disciplines, including the fields of veterinary medicine, epidemiology, microbiology, 
clinical medicine and immunology.
The aim of this thesis is to describe observations on epidemiology, clinical aspects and long 
term health outcomes of Q fever patients diagnosed in the initial stages of the first Dutch 
human Q fever outbreak. Additionally, this thesis aims to describe the performance and 
potential clinical use of a newly developed diagnostic Q fever interferon gamma release 
assay, the Coxiella ELISPOT, which measures the host’s cellular immune reponse to Coxiella 
burnetii. 
Chapter 1. provides a general introduction and contains background information on Q 
fever; its pathogenesis, clinical manifestations and long-term sequelae, the host’s immune 
response to C. burnetii, and the impact and scope of the Dutch human Q fever outbreak.
Q fever is considered a new and emerging zoonosis in the Netherlands. Retrospective 
serological studies performed on available samples from the period leading up to the first Q 
fever outbreak in the Netherlands show a low seroprevalence of antibodies againt C. burnetii. 
However, the highly epidemic municipalities in the epidemic’s epicentre in the province of 
Noord-Brabant were excluded from this analysis. 
Chapter 2. reports on the aetiology of clinically treated pneumonia cases in the epicentre of 
the first Q fever outbreak in 2007, showing the emergence of C. burnetii as a novel causative 
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agent of pneumonia in this area. The contribution of C. burnetii as a causative agent of 
pneumonia in patients admitted to Bernhoven Hospital (Herpen lies within the catchment 
population of this community-based hospital) in the period January-July 2007 was assessed 
by retrospectively testing available patients’ sera for the presence of C. burnetii antibodies. Of 
the total of 95 clinical pneumonia cases, C. burnetii was the causative agent in 21 (22%). The 
number of Q fever pneumonia cases in May (n=13) was significantly higher than in any other 
month of the study period (range 0-5). To examine these findings in a historical perspective, 
data on number of pneumonia cases treated at Bernhoven Hospital were retrieved from 
the local diagnosis registration system. In the 2 years preceding the outbreak, the number 
of pneumonia cases was stable with expected seasonal variation in 2005 (206 cases) and 
2006 (170 cases), but with no sharp increase as was observed in 2007 (n=272). The findings 
in this study support the hypothesis that C. burnetii emerged as a novel etiological agent of 
pneumonia in the epidemic area in the Netherlands in May 2007. 
The clinical presentation, diagnosis including antibody response and clinical outcome 
of Q fever in the Netherlands were unknown at the onset of the first epidemic wave in 
2007. Available literature on the disease in its acute and chronic form, its diagnosis and 
management, was mostly retrospective and mainly derived from a single reference centre 
of expertise in France. In order to provide a uniform and systematic clinical follow-up for the 
Dutch Q fever patients from the first outbreak, Q fever patient care was centralized in and 
coordinated from the GP practice of Herpen, a rural town in the province of Noord-Brabant, 
and the epicentre of the first outbreak.
Chapter 3. describes clinical presentation, serology and echocardiographic findings of Q 
fever patients (n=85) from the first outbreak, who received follow-up at the GP practice in 
Herpen. An aspecific flu-like illness was the most common clinical presentation. Persistent 
fatigue after acute Q fever was present in 59% at 6 months and in 30% at 12 months follow-
up. A typical serological response pattern was noted in both phase I and phase II antibodies, 
showing an increase in antibody titres up to 3 months, and a subsequent decline in the 
following 9 months of follow-up. None of the patients developed chronic Q fever. As could 
be expected on the basis of known background prevalence of minor cardiac valve defects 
in the general population, baseline echocardiography revealed a similarly high background 
prevalence of mild, clinically insignificant cardiac valve defects in this Q fever patient 
population. In the setting of a large outbreak, screening echocardiography is no longer part 
of the standard work-up of Q fever patients.
Chapter 4. describes the echocardiographic findings and outcomes of a larger group of 
Q fever patients from both the 2007 and 2008 cohort (n=134). Again a high proportion of 
clinically insignificant valvular defects were found and no patients developed chronic Q 
fever. By contrast with existing publications, these data indicate a low risk of progression 
to Q fever endocarditis. This contrasting result may be explained by selection bias and lack 
of specification of valvular defect severity in published retrospective research. In the setting 
of a massive Q fever outbreak, this raises the question whether the harm of low-treshold 
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administration of long-term antibiotic prophylaxis for mild valvular defects outweighs the 
benefit. In addition, the associated health-care costs of such a follow-up strategy on a large 
scale are substantial.
Following the observation of a striking level of undue long-term fatigue in many of the Q 
fever patients who were followed-up at the GP practice in Herpen (as described in Chapter 
3.) two studies were undertaken to further characterize this symptomatology and its impact 
on health status.  
In Chapter 5. the health status of Q fever patients from the first outbreak cohort is studied 
in detail. Health status was assessed with the Nijmegen Clinical Screening Instrument (NCSI). 
All patients were serologically tested for C. burnetii antibodies. Using a case-control design 
the study showed a sustained decrease in many aspects of health status 1 year after primary 
infection. Q fever patients had significantly more problems on the subdomains of symptoms 
and functional impairment. Severe fatigue levels were present in 52% of patients versus 26% 
in seronegative controls (p<0,05). NCSI score did not differ between seronegative (n=23) and 
seropositive (n=11) controls. These data support a sustained decrease in health status of 
Dutch Q fever patients after 1 year of follow-up.
For the patients of the Dutch Q fever outbreak, it remained unknown whether impaired 
health status and symptomatology persist (very) long-term or can change over time in the 
individual patient.  
In Chapter 6. the health status of the same cohort of patients from the 2007 outbreak is 
studied 4 years after acute Q fever. A persistent significant percentage of patients exhibited 
clinically relevant (“severe”) scores for all sub-domains of the NCSI. After 4 years, undue 
fatigue was present in 46% and exactly half of all patients experienced a severly impaired 
general quality of life. Patients with NCSI scores available in both 2008 and 2011 showed no 
difference in all sub-domain scores, except for a small decrease in dyspnoea emotions in 
2011. In this group, a significant proportion of patients either improved or worsened in one 
or more sub-domains of health status. A minority of Q fever patients with impaired health 
status in 2008 showed improvement in various sub-domains of health status in 2011, but at 
the group level this effect was cancelled out by patients with worsening scores. These data 
support an overall persistence of impaired health status of Q fever patients in the Netherlands 
4 years after primary infection. 
Chapter 7. deals with the development and validation of the Coxiella ELISPOT; a Coxiella 
burnetti specific interferon gamma release assay (IGRA) measuring C. burnetii specific 
T-cell responses to both C. burnetii phase I and phase II antigens. Definitively establishing 
a diagnosis of chronic Q fever remains challenging, as the diagnostic performance of both 
conventional serological tests and PCR is limited. Given the importance of an early diagnosis 
of chronic Q fever, there is a need for a reliable diagnostic test.
The Coxiella ELISPOT adequately identified convalescent Q fever patients (n=9) from healthy 
controls (n=9). Compared to convalescent Q fever patients, chronic Q fever patients (n=3) 
showed a distinct Coxiella ELISPOT profile characterized by a much higher spot count for 
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both phase I and phase II (18-fold for phase II, 8-fold higher for phase I) andf a consistent shift 
towards more phase I reactivity. The diagnostic potential of the Coxiella ELISPOT is promising 
and warrants further investigation. 
Following development and publication of another Q fever specific IGRA (the Whole Blood 
Interferon-Gamma Production Assay) by Schoffelen et al. in 2013, a comparison study was 
performed to assess the diagnostic performance of both tests in diagnosing Q fever. 
In Chapter 8. the Coxiella ELISPOT is compared to a different whole blood C. burnetii specific 
IGRA in terms of diagnostic potential. Both tests were performed in a well-defined patient 
group of chronic Q fever patients (n=16) and a group of healthy seronegative individuals 
(n=17). Among patients, both tests detected a positive response in 14 out of 16 patients. 
Among controls, none were positive in the Coxiella ELISPOT whereas the Whole Blood Assay 
detected positive results in 1/17 and 3/17 individuals, when using Henzerling and Nine Mile 
as stimulating antigens, respectively. These data suggest that the Coxiella ELISPOT has a 
somewhat higher specificity than the Whole Blood Assay when Nine Mile is used as antigen 
stimulus. The assays showed moderate corrrelation: the Spearman correlation coefficient 
ranged between 0,37-0,60, depending on the antigen used. Further investigation of the 
diagnostic potential for C. burnetii infection of both assays is warranted.
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De eerste Nederlandse menselijke Q koorts gevallen in de lente van 2007 waren het begin van 
een massale epidemie die zich in jaarlijkse seizoensgebonden uitbraken zou ontwikkelen 
tot 2011. De opkomst van Coxiella burnetii als een humaan pathogeen op deze onvoorziene 
schaal werd in verband gebracht met door Q koorts veroorzaakte abortus-golven op geiten- 
en schapenmelkbedrijven die al startten in 2005. In 2011, omvatte de Q koorts uitbraak meer 
dan 4000 gemelde Q koorts patiënten en een geschatte 44000 niet gemelde Q koorts gevallen. 
Aan het begin van de Nederlandse epidemie waren er geen evidence-based gevalideerde 
diagnose- en behandelprotocollen voorhanden. Beschikbare literatuur was tot dan toe 
hoofdzakelijk gegenereerd door een onderzoeksgroep van het WHO referentie laboratorium 
voor Q koorts in Marseille, Frankrijk. Het was onduidelijk of deze onderzoeksbevindingen 
toepasbaar waren in de setting van de massale uitbraak in Nederland. Enerzijds was dit een 
grote uitdaging voor clinici en andere gezondheidsprofessionals in het management van acute 
Q koorts en het voorkomen van lange-termijn gevolgen in de vroege fase van de epidemie. 
Anderzijds bood de Q koorts uitbraak een ongekende kans voor onderzoekers van verschillende 
disciplines om deze complexe infectieziekte te observeren, te verkennen en te onderzoeken.
Het doel van dit proefschrift is een beschrijving te geven van observaties over epidemiologische 
en klinische aspecten en lange-termijn gezondheidsuitkomsten van Q koorts patiënten van 
de initiële fase (2007-2008) van de eerste Nederlandse Q koorts uitbraak. In aanvulling hierop 
is het doel van dit proefschrift een beschrijving te geven van de diagnostische ‘performance’ 
en mogelijke klinische toepassingen van een nieuw ontwikkelde diagnostische interferon-
gamma release test voor Q koorts: de Coxiella ELISPOT. 
Hoofdstuk 1. geeft een algemene introductie en bevat achtergrondinformatie over Q koorts; 
de pathogenese, klinische manifestaties en lange termijns-gevolgen, de immuunrespons van 
de gastheer tegen C. burnetii en de impact en omvang van de Nederlandse humane Q koorts 
uitbraak.
In Nederland wordt Q koorts beschouwd als een nieuwe zoönose. In aanloop naar de eerste 
Q koorts uitbraak in Nederland in 2007 was de seroprevalentie van C. burnetii specifieke 
antistoffen laag in de algemene populatie. Echter, de gemeentes in het episch centrum van 
de epidemie waren niet vertegenwoordigd in deze seroprevalentie studie.
In hoofdstuk 2. wordt de etiologie van klinisch behandelde pneumonie gevallen in het 
episch centrum van de eerste Q koorts uitbraak in 2007 onderzocht en wordt de opkomst 
van C. burnetii als nieuw oorzakelijk agens van pneumonie aangetoond. De bijdrage van C. 
burnetii als oorzaak van pneumonie bij patiënten behandeld in het Bernhoven ziekenhuis 
(Herpen ligt in het adherentiegebied van dit algemeen ziekenhuis) in de periode januari-
juli 2007 werd getest door retrospectief patiënten-sera te testen op de aanwezigheid van C. 
burnetii antistoffen. Van de 95 klinische pneumonie gevallen was C. burnetii het oorzakelijk 
pathogeen in 21 patiënten (22%). Het aantal Q koorts pneumonie gevallen in mei (n=13) was 
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aanmerkelijk hoger dan in elke andere maand in de studie periode (range 0-5). Om deze 
data in een historisch perspectief te onderzoeken werd retrospectief data over het aantal 
pneumonie gevallen in het Bernhoven ziekenhuis van de voorafgaande 2 jaar verzameld. In 
de 2 jaar voorafgaand aan de epidemie van 2007 was het aantal pneumonie gevallen stabiel 
met een verwachte seizoensgebonden variatie in 2005 (n=206) en 2006 (n=170), maar niet 
met een scherpe stijging in mei zoals waargenomen in 2007 (n=272). De bevindingen in deze 
studie ondersteunen de hypothese dat C. burnetii opgekomen is als een nieuwe oorzaak van 
pneumonie in het epidemisch gebied in mei 2007. 
De klinische presentatie, diagnose inclusief antistof respons en klinische uitkomst van Q koorts 
in Nederland was onbekend bij aanvang van de eerste uitbraak in 2007. Om een uniforme 
en systematische follow-up te regelen voor de eerste Nederlandse Q koorts patiënten werd 
de patiëntenzorg gecentraliseerd en gecoördineerd in de huisartsenpraktijk te Herpen, een 
kleine gemeente in Noord-Brabant in het episch centrum van de eerste uitbraak.
Hoofdstuk 3. beschrijft de klinische presentatie, serologie en echocardiografische 
bevindingen van Q koorts patiënten (n=85) van de eerste uitbraak opgevolgd in de 
huisartsenpraktijk te Herpen. Een aspecifieke griepachtig beeld was de meest frequente 
klinische presentatie. Aanhoudende moeheid na acute Q koorts was aanwezig in 59% na 
6 maanden en in 30% na 12 maanden follow-up. Er werd een karakteristiek serologische 
respons patroon waargenomen voor zowel fase I als fase II antistoffen, met een toename in 
antistoftiter tot 3 maanden en een daling in de daaropvolgende 9 maanden. Geen van de 
patiënten ontwikkelde chronische Q koorts. Zoals werd verwacht op basis van een bekende 
hoge prevalentie van milde hartklepgebreken in de algemene populatie, liet echocardiografie 
een hoge prevalentie zien van milde, klinisch onbelangrijke hartklepgebreken in dit Q koorts 
patiënt cohort. In de setting van een grote uitbraak is screening echocardiografie niet langer 
onderdeel van de standaard work-up van Q koorts patiënten. 
Hoofdstuk 4. beschrijft de echocardiografische bevindingen en uitkomsten van een grotere 
groep Q koorts patiënten van zowel het 2007 en 2008 patiënten-cohort (n=134). Wederom 
werd een hoge prevalentie gevonden van milde, klinisch onbelangrijke hartklepgebreken 
gevonden en geen van de patiënten ontwikkelde chronische Q koorts. In tegenstelling tot 
beschikbare literatuur waarin een hoog risico tot ontwikkelen van Q koorts endocarditis bij 
klepgebreken wordt beschreven, wijzen deze data op een veel lager risico. In de setting van 
een massale Q koorts uitbraak roept dit de vraag op of de risico’s van het laagdrempelig 
toedienen van langdurige antibiotische profylaxe (12 tot 18 maanden) opweegt tegen de 
mogelijke voordelen. Ook de kosten die gepaard gaan met een dergelijke follow-up strategie 
op deze schaal zijn aanzienlijk.
Een aanzienlijk deel van de Q koorts patiënten van de eerste Nederlandse Q koorts uitbraak 
hadden last van aanhoudende vermoeidheid (zoals beschreven in hoofdstuk 3). De 
hiernavolgende twee studies werden uitgevoerd om deze vermoeidheid en de gevolgen voor 
de gezondheidsstatus van Q koorts patiënten verder te onderzoeken.
Hoofdstuk 5. beschrijft gedetailleerd de gezondheidsstatus van Q koorts patiënten van het 
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eerste uitbraak cohort (n=54). De gezondheidsstatus werd gemeten met het Nijmegen Clinical 
Screening Instrument (NCSI). Patiënten en controles werden serologisch gecontroleerd. 
Van de 34 controle proefpersonen bleken 11 positieve C. burnetii serologie te hebben. Met 
behulp van een case-control design werd een vermindering van meerdere aspecten van de 
gezondheidsstatus gevonden. Q koorts patiënten hadden significant meer problemen in de 
sub-domeinen ‘symptomen’ en ‘functionele beperking’. Ernstige vermoeidheid was aanwezig 
in 52% van de patiënten (n=54) tegen 26% in seronegatieve controle proefpersonen (n=23) 
(p<0,05). De NCSI scores verschilden niet tussen seropositieve (n=11) en seronegatieve (n=23) 
controle proefpersonen. Deze studie laat een duidelijke vermindering in gezondheidsstatus 
zien van Q koorts patiënten 1 jaar na acute Q koorts.
Het is onbekend of de vermindering in gezondheidsstatus van Q koorts patiënten aanhoudt 
op de zeer lange termijn (na 1 jaar) en of de gezondheidsstatus van een individuele patiënt 
kan variëren in de tijd.
Hoofdstuk 6. beschrijft de gezondheidsstatus van hetzelfde cohort Q koorts patiënten 
van de uitbraak in 2007 na 4 jaar follow-up. De gezondheidsstatus werd gemeten met 
het Nijmegen Clinical Screening Instrument (NCSI). NCSI scores in 2008 (n=54) en 2011 
(46) werden vergeleken op het niveau van de groep en op individueel patiënt-niveau. Een 
groot deel van de patiënten vertoonden klinisch relevante (‘ernstige’) scores voor alle 
sub-domeinen van het NCSI. Na 4 jaar was overmatige vermoeidheid aanwezig in 46% en 
precies de helft van alle patiënten hadden een ernstig vermindering in algehele ‘quality 
of life’. Voor patiënten met scores in 2008 en 2011 (n=37) was er geen verschil in alle sub-
domein scores, met uitzondering van een vermindering van ‘dyspneu emoties’ in 2011. Een 
significant deel van patiënten in deze groep (n=37) verbeterden of verslechterden in een of 
meerdere sub-domeinen van de gezondheidsstatus. Een minderheid van Q koorts patiënten 
met verminderde gezondheidsstatus in 2008 vertoonde een verbetering in verschillende 
sub-domeinen van het NCSI in 2011, maar op groepsniveau werd dit effect tenietgedaan 
door patiënt met verslechterende scores. Deze data tonen een aanhouden van verminderde 
gezondheidsstatus van Nederlandse Q koorts patiënten 4 jaar na acute Q koorts. 
Hoofdstuk 7. beschrijft de ontwikkeling en validatie van de Coxiella ELISPOT; een Coxiella 
burnetii specifiek interferon-gamma release assay (IGRA) die de C. burnetii specifieke T-cel 
respons op zowel C. burnetii fase I en fase II antigenen. Het stellen van een definitieve 
diagnose chronische Q koorts is uitdagend omdat de diagnostische waarde van serologie en 
PCR beperkt is. Het stellen van de diagnose chronische Q koorts is belangrijk voor een tijdige 
behandeling en het voorkomen van complicaties.
De Coxiella ELISPOT onderscheidde nauwkeurig convalescente Q koorts patiënten (patiënten 
met een doorgemaakte, niet chronische infectie) (n=9) van gezonde controle proefpersonen 
(n=9). Vergeleken met convalescente proefpersonen vertoonden patiënten met chronische 
Q koorts (n=3) een karakteristiek Coxiella ELISPOT profiel met een veel hogere spot-count 
voor zowel fase I (8-voudig verhoogd) als fase II (18-voudig verhoogd) antigenen, en een 
consistente verschuiving richting meer fase I reactiviteit. De diagnostische waarde van de 
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Coxiella ELISPOT is veelbelovend en verdient verder onderzoek. 
Na de ontwikkeling en publicatie van een andere Q koorts specifiek IGRA (the Whole Blood 
Interferon-Gamma Production Assay) door Schoffelen et al. in 2013 werd een vergelijkende 
studie uitgevoerd om de diagnostische ‘performance’ van beide assays te meten in het 
diagnosticeren van een C. burnetii infectie.
In hoofdstuk 8. wordt de diagnostische ‘performance’ vergeleken van de Coxiella ELISPOT 
met de ‘Whole Blood Interferon-Gamma Production Assay’. Beide assays werden uitgevoerd 
in een strikt gedefinieerde groep patiënten met chronische Q koorts (n=16) en een groep 
gezonde seronegatieve proefpersonen (n=17). In de patiëntengroep identificeerde beide 
assays een positieve respons in 14 van de 16 patiënten. In de controle groep was geen van 
de proefpersonen positief in de Coxiella ELISPOT assay. De Whole Blood Assay was positief 
in 1/17 en 3/17 controle proefpersonen wanneer respectievelijk de ‘Henzerling’ of ‘Nine Mile’ 
gebruikt werd als stimulerend antigen. Deze data suggereren dat de Coxiella ELISPOT een iets 
hogere specificiteit heeft dan de Whole Blood Assay als ‘Nine Mile’ als stimulerend antigen 
gebruikt wordt. De assays vertoonden een matige correlatie: de Spearman correlatie coëfficiënt 
varieerde tussen 0,37-0,60, afhankelijk van welk stimulerend antigen werd gebruikt. 
Conclusies
Dit proefschrift bevat verkennende studies over Q koorts bij mensen, met een accent op 
klinische observaties, lange-termijn gezondheidsstatus na infectie en de ontwikkeling van 
een nieuwe diagnostische test voor Q koorts. 
De bevindingen in dit proefschrift ondersteunen de hypothese dat Coxiella burnetii is 
opgekomen in Nederland als een nieuwe oorzaak van pneumonie in mei 2007. De eerste 
systematische observaties van klinische presentatie, serologie en echocardiografische 
bevindingen bij Q koorts patiënten van de initiële fase van de uitbraak in Nederlands worden 
gepresenteerd. 
Q koorts manifesteerde zich voornamelijk als een mild griepachtig ziektebeeld. De prevalentie 
van milde hartklepgebreken bij Q koorts patiënten was hoog maar vergelijkbaar met de 
verwachte prevalentie in de algehele bevolking. De incidentie van chronische Q koorts in het 
geval van deze milde, klinisch niet belangrijke hartklepvitia was veel lager dan eerder werd 
aangenomen. Dit roept de vraag op of echocardiografische screening en het toedienen van 
langdurige antibiotische profylaxe in het geval van deze milde hartklepgebreken nuttig is. 
En groot deel van de Q koorts patiënten heeft last van overmatige vermoeidheid en een 
aanhoudend verminderde gezondheidsstatus na 1 en 4 jaar follow-up. 
Het meten van de C. burnetii specifieke interferon-gamma productie door menselijke T-cellen 
is haalbaar en heeft diagnostisch potentieel voor het diagnosticeren van een C. burnetii 
infectie. Een vergelijking van twee C. burnetii specifieke IGRA’s; de Coxiella ELISPOT en de 
Whole Blood Interferon Gamma Production Assay, laat een hoge sensitiviteit zien voor het 
detecteren van een C. burnetii specifieke interferon-gamma respons bij chronische Q koorts 
patiënten. Nader onderzoek naar het diagnostisch potentieel van beide testen is aan te bevelen.
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